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Early impact of HPV vaccination at the population level:                                                         
HPV genotypic prevalence in U.S. women from pre- and post-vaccine periods, 2003-2010 
 
Michael H. Marco 
 The broad aim of this dissertation is to understand the early impact of HPV vaccination in 
females at the population level.  Three important public health questions are addressed: 1) Is 
HPV vaccination doing what is expected: decreasing the prevalence of vaccine-type HPV 6, 11, 
16 and 18 which are etiologically linked to invasive cervical cancer and genital warts?; 2) Is 
there evidence of beneficial cross-protection (decreased prevalence) of any of the other non-
vaccine-targeted high-risk (HR) HPV genotypes?; and 3) With the expected decline of HPV 16 
and 18, are there deleterious virological consequences, such as type-replacement (increased 
prevalence) with a rise of non-vaccine-targeted HR HPV?  In the first chapter, I assess and 
synthesize peer-reviewed literature published from 2007 to 2013 that documented early impact 
of HPV vaccination.  Seventeen ecological studies were stratified into three tiers based on degree 
of vaccination impact (cervical abnormalities, genital warts, and HPV DNA) and incidence or 
prevalence in samples from a pre-HPV vaccination time period (pre-2007) with that of a post-
vaccination time period (post-2007) were compared.  In the second chapter, I investigate 
vaccine-type HPV prevalence changes between pre- and post-vaccine periods in over 8,000 
females aged 14-59 years enrolled in the NHANES HPV Vaginal Swab Surveys from 2003-
2010.  In the third chapter, I test for evidence of non-vaccine-targeted HR HPV genotypic cross-
protection and type-replacement in NHANES Survey females from the pre- and post-vaccine 
periods.  Finally, I conclude the dissertation with a summary of the findings and a discussion of 
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 Human papillomavirus (HPV) is a small double-stranded DNA virus, which infect 
cutaneous and mucosal epithelial cells.  HPV is by far the most common sexually transmitted 
disease in the U.S. with approximately 6.2 million individuals infected yearly.
1
  Sexual 
activity—often within the first 6 months of sexual debut—is the most pronounced risk factor for 
incident HPV infection in a female’s genital tract.
2,3
  HPV infection is age-dependent
4
 and 
detected most often in sexually-active females aged 20-24 years.
5
  
 Of the approximately 120 HPV types that have been identified, 40 types sort into 15 
alpha species which infect the genital tract.
6
  These 40 HPV types are divided into two groups: 
high-risk (HR), also referred to as oncogenic or carcinogenic, and low-risk (LR).  HR HPV 
genotypes have been etiologically linked to invasive cervical cancer (ICC), as well as vaginal, 
vulvar, penile, anal and a subset of head and neck cancers.
7-9
  
 ICC is the fourth most common cancer in U.S. females, with approximately 530,000 
cases diagnosed yearly.
10
   It is, however, the number one cancer in sub-Saharan African and 
South-east Asian females because high quality screening and early and effective treatment are 
sparse to non-existent.
11
   In 2012, the World Health Organization (WHO) estimated that ICC 
was responsible for approximately 270,000 deaths worldwide.
10
 
 The WHO’s International Agency for Research (IARC) acknowledges that there are 20 
HPV HR genotypes with varying levels of carcinogenicity:  HPV 16, 18, 26, 31, 33, 35, 39, 45, 
51, 52, 53, 56, 58, 59, 66, 67, 68, 70, 73, and 82.
12
  The most commonly detected HPV types 
found in ICC tissue, in descending order of frequency, are HPV 16, 18, 45, 31, 33, 52, 58, and 
35.
8
  HPV 16 and 18 are overwhelmingly the HR types most strongly associated with 
approximately 70% of ICC.
13,14





adenocarcinoma of the cervix.
14,15
  Approximately 40% of women who repeatedly test HPV 
positive (referred to as “persistent”) for type-16 will go on to develop high-grade (precancerous) 
cervical intraepithelial neoplasia (CIN).
16
  Moreover, there is a twelvefold increase in the risk of 
developing high-grade CIN in females with persistent HPV 16 and/or 18 infection compared to 
other HR HPV genotypes.
17
  Stage-3 CIN left untreated for many years can invade the base 
membrane of the epithelium and cause cervical cancer.
18,19
  
 The 20 HPV types classified as LR HPV include HPV 6, 11, 32, 40, 42, 43, 44, 54, 55, 
61, 62, 64, 71, 72, 74, 81, 83, 84, 87, and 89.
20
  LR HPV 6 and 11 are associated with 90% of 
penile, vaginal, and anal warts.
21
  Genital warts (GWs) are often the immediate clinical 
manifestation of incident HPV infection.
22
  While GWs are easily treatable in an out-patient 
setting, the psychological burden caused by GWs, as well as the annual cost to health care 
systems, should not be underestimated.
23,24
  
 HPV prophylactic vaccination against HPV 6, 11, 16, and 18 has existed in the U.S. since 
2006.  Routine vaccination is recommended for all individuals aged 11 or 12 years, and catch-up 
vaccination for females aged 13 through 26 years and males aged 13 through 21 years.
25-27
  The 
three U.S. Food and Drug Administration (FDA)-approved, commercially available vaccines 
differ in the number of specific HPV genotypes they prevent; however, all target HPV 16 and 18.  
Pivotal studies of the three vaccines reported 90-98% vaccine efficacy on all endpoints (e.g., 





 Evidence of HPV genotypic cross-protection against cervical lesions due to HPV non-
vaccine HR types in the phase III studies of the first two FDA-approved vaccines has been 
reported.
32,33





to a new ecological niche created by a reduction in the prevalence of HPV genotypes 16 and/or 
18 is an important subject of concern being discussed in the HPV vaccine community.
34,35
   To 
date, however, no data exist to support this occurring.
36,37
   
 With a median age of 49 years for ICC in the U.S.,
38
 it will be approximately 25 years 
until significant clinical benefit of HPV vaccination—namely, a reduction in ICC incidence—
can be established.  Monitoring temporal trends in the prevalence of HPV 16 and 18 as well as 
other HR HPV genotypes is the surest and easiest way of monitoring early vaccine impact at the 
population level.
39
  Hence, the broad aim of this dissertation is to understand the early impact of 
HPV vaccination in females at the population level.  Three important public health questions will 
be examined: 1) Is HPV vaccination doing what is expected: decreasing the prevalence on 
vaccine-type HPV 16 and 18; 2) Is there evidence of beneficial cross-protection (decreased 
prevalence) of any of the other 20-30% of HR HPV genotypes etiologically linked to ICC?; and 
3) With the expected decline of HPV 16 and 18, are there deleterious virological consequences, 
such as type-replacement with a rise in prevalence of other HR HPV genotypes?   
 Chapter 2 provides a systematic review that summarizes and synthesizes the population-
based, early impact of HPV vaccination after licensure in 2006.  While many systematic reviews 
and meta-analyses on the cost effectiveness of HPV vaccination exist,
40-43
  there are no published 
systematic reviews investigating the early impact of HPV vaccination from countries with 
widespread vaccine utilization.  This systematic review will also include background and a non-
systematic review of evidence for potential biological mechanisms through which HPV 






 My review includes ecological studies in diverse female patient populations from the 
U.S., Europe, and Australia and New Zealand that compare virologic changes in LR and HR 
HPV genotypic prevalence as well as differences in the incidence of HPV clinically-related 
outcomes (e.g., GWs or CIN 2/3) between the pre- and post-vaccine eras.  Documented changes 
in vaccine-type HR HPV prevalence and incidence of GWs before and after the advent of the 
vaccine are distinctive indicators for observing initial vaccine effectiveness.
39
   
 If a majority of the studies analyzed point in a positive direction, suggesting that 
vaccination is likely reducing the prevalence of vaccine-type HR HPV infection and decreasing 
GWs or cervical abnormalities in populations where the vaccine has been available for 
approximately ~10 years, pediatricians can use this information in a more proactive way to 
explain to parents the benefits of HPV vaccination for their daughters.  In turn, increased female 
vaccination resulting from parental education of the vaccine’s cancer-preventing qualities will 
undoubtedly help normalize and escalate HPV vaccine uptake in males for preventing anal, 
penile, and head and neck cancers.  
 Journal articles are categorized into three tiers according to degree of 
outcome/vaccination impact (clinical vs. virological changes) and qualify for review if they have 
data comparing outcomes on well-defined patient populations specifically before and after 2006. 
Studies with GW data on males are included and analyzed.  Because HPV vaccination in males 
is relatively new, and widespread use is still uncommon, a decrease in heterosexual male GW 
incidence in countries where female vaccination coverage is high could suggest the effect of herd 
immunity.
44
  Finally, the review adheres to practices as stipulated in the Preferred Reporting 







 In Chapter 3, I begin my ecological assessment of the relationship between HPV 
vaccination and the expected outcome of decreased prevalence of vaccine-type HR HPV in the 
pre- and post-vaccine eras (2003-2006 vs. 2007-2010).  Unlike other analyses which specially 
focus on HPV prevalence in adolescents or include only a smattering of older females,
36,37,46
 I 
explicitly aim to cast a wider net to look at a broader age range of females (age 14-59 years) and 
also categorize them by specific age groups.  My analyses of temporal trends of HPV genotypic 
prevalence will specifically control for prior vaccination, race, education level, sexual activity, 
and marital status.   
 Chapter 3 also includes a geographical ecological assessment to determine if the 
prevalence of vaccine-type HR HPV now differs in the post-vaccine era between the top-10 U.S. 
states with the highest reported coverage of HPV vaccination in females compared with the 
bottom-10 states with the lowest reported coverage of HPV vaccination.  I hypothesize that the 
top-10 states with the highest vaccine coverage will show a larger decrease in HR vaccine-type 
HPV prevalence in the post-vaccine period than the bottom-10 states with the lowest vaccine 
coverage. This would be another early indication that the vaccine is doing what it should.  
 Chapter 4 employs the same temporal trend methodology of examining HPV genotypic 
prevalence for evidence of non-vaccine-targeted HR HPV cross-protection and type-replacement 
in females at the population level.  An analysis will be conducted to assess the relationship 
between vaccination and the beneficial outcome of cross-protection (decreased prevalence) of 
non-vaccine-targeted HR HPV genotypes from the alpha-7 and alpha-9 species.  HPV 16 exists 
in the alpha-9 species that includes five HR HPV genotypes (HPV 31, 33, 35, 52, and 58), and 
HPV 18 is from the alpha-7 species which has four HR HPV genotypes (39, 45, 59, and 68).
47
  







 Varying degrees of decreased prevalence of these five genotypes —signifying cross-




 In addition to my examination of HR HPV genotypic cross protection, I will test for type-
replacement—increased prevalence of non-vaccine-targeted HR HPV from the alpha-7 and 9 
species.  It might be too early to document viral type-replacement while still in the first decade of 
wide-spread HPV vaccination.  Nevertheless, examining this effect at the population level is 
prudent as it would provide public health officials with a robust sense of urgency for continuing 
to recommend routine cervical cancer screening in vaccinated females.   
 Unlike a previously published ecological study examining HR HPV cross-protection and 
type-replacement in females aged 14-19 years, my analyses will include those up to age 59 years.  
Lastly, all documentation of HPV prevalence will be adjusted for well known risk factors, 
including education, sexual activity, and marital status.  
 Chapter 5 includes a summary and discussion of the data analyses from my empirical 
papers and systematic review.  It also explains the public health implications and offers 
recommendations for future research.  The analyses planned for my dissertation add to an 
existing array of published mathematical modeling research
48-53
 and a growing body of ecologic 
studies investigating the early impact of HPV vaccination.
36,37,46,54-57
  Noteworthy differences in 
my research are an investigation of vaccine impact on a much broader age range of females and 
examining, for the first time, possible geographic differences in HR vaccine-type HPV 
prevalence based on rates of vaccine coverage.  A significant strength of this research is the 





characterized population-based survey containing over 8,000 U.S. females.  No other national 
survey from the U.S. or internationally with such rigorous sampling methods and excellent 
laboratory quality control comparing past and present HPV DNA prevalence exists.  
 This dissertation is an investigation of temporal trends of HR HPV genotypic prevalence 
before and after the advent of wide-spread HPV vaccination in females at the population level.  
The systematic literature review offers an in-depth look at the vast assortment of international 
ecological studies documenting differences in the incidence and prevalence of HPV virological 
and early-stage clinical outcomes between the pre- and post-vaccine eras.  My empirical papers 
examine 1) the expected decrease in HPV vaccine-type prevalence; 2) the beneficial occurrence 
of non-vaccine-targeted HR HPV cross-protection; and 3) the deleterious effect of non-vaccine-
targeted HR HPV type replacement.  While it is too early to determine if HPV vaccination in 
females (and now in males) has had an impact in preventing cervical and other less common 
HPV-associated cancers, monitoring of changes in HPV prevalence at the population level is an 
integral part of the spectrum of initial outcomes of HPV vaccination which has obvious and 
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2.0 Chapter 2: 
Early impact of HPV vaccination at the population level: systematic review comparing 








 Human papillomavirus (HPV) is a necessary cause of invasive cervical cancer (ICC). 
Vaccination against ICC began in 2006 with the commercial availability of the HPV 
quadrivalent vaccine, Gardasil.   Gardasil is also targeted to prevent genital warts (GW).  It will 
be approximately 25 years until significant clinical benefit of HPV vaccination—namely, a 
reduction in ICC incidence—can be established.  However, scattered reports of decreased GW 
incidence in post-vaccine era populations have been published since 2009.   
Methods 
 A systematic literature search of English language peer-reviewed journal articles 
published from 2007 to 2013 was conducted employing MEDLINE®, PubMed® and Scopus® 
to document the early impact of HPV vaccination.  Studies were stratified into three tiers based 
on degree of vaccination impact (clinical vs. virological changes).  Studies comparing incidence 
or prevalence in a pre-HPV vaccination time period (pre-2007) with that of a post-vaccination 
time period (post-2007) were included along with studies which included physician-verified 
vaccinated versus unvaccinated populations.  While the primary goal of this review was to 
determine incidence or prevalence change in females (the overwhelming majority of vaccine 
recipients), studies which also included data on males were used.   
Results 
 Of the 17 studies included in the final review, two detailed changes in cervical 





incidence or prevalence (tier 2); and four described change of HPV vaccine-type genotypic 
prevalence, i.e., HPV 6, 11, 16, or 18 (tier 3).  Almost all of the studies were ecological in nature, 
with a few being cohorts (multi-clinic data analyses), and one using a cross-sectional design.  
Ten of 17 studies included patient vaccination status, and most mentioned that Gardasil was 
being used >80% in their patient population.  Ten of the 11 HPV genital wart incidence studies 
included males with only three (all Australian) categorizing them as men who have sex with 
women (MSW) or men who have sex with men (MSM).  All 17 studies from the three tiers 
documented varying amounts of decreased incidence or prevalence in their post-vaccine era 
patients, namely those in youngest categorized age groups (<21 years).  Five documented 
decreased GWs in males.  Interestingly, the three studies categorizing males by sexual 
orientation noted a decreased incidence in MSW but not in MSM.     
Conclusion 
 Similar to the positive trend observed in published results of HPV vaccine mathematical 
modeling studies, all 17 studies analyzed in this review documented decrease in either HPV 
vaccine-like genotype prevalence, genital wart incidence, or cervical intraepithelial neoplasia at 
the population level.  At a first glance ~10 years after the advent and widespread use of HPV 
vaccination, it is encouraging to observe decreased trends in HPV virologic and clinical 









Low-risk and High-risk HPV Associate with Genital Warts and Cervical Cancer 
 Of the estimated 120 human papillomavirus (HPV) genotypes identified, 40 types are 
known to infect the genital tract.
1
  HPV is by far the most common sexually transmitted disease 
in the U.S. with approximately 6.2 million individuals infected yearly.
2
   The 40 HPV types that 
infect the genital tract are categorized into two groups: high-risk (HR), also referred to as 
oncogenic or carcinogenic, and low-risk (LR).  Up to 20 HR types
1
 have been etiologically 
linked to invasive cervical cancer (ICC), vaginal, vulvar, penile, anal, and a subset of head and 
neck cancers.
3-10
   
 In the U.S., ICC is the fourth most common cancer in females, with approximately 
530,000 cases diagnosed yearly.
11
   It is, however, the number one cancer in sub-Saharan African 
and Southeast Asian females because high quality screening and early and effective treatment are 
sparse to non-existent.
12
   In 2012, the WHO estimated that ICC was responsible for a 
approximately 270,000 deaths worldwide.
13
  
 Two HR types, HPV 16 and 18, are considered responsible for approximately 70% of 
ICCs worldwide.
14
  HPV 16 is found in tissue in over 50-55% of ICCs whereas type-18 is most 
strongly associated with adenocarcinoma of the cervix.
14,15
   The propensity for HPV 16 
infection to lead to high-grade (precancerous) cervical intraepithelial neoplasia (CIN) compared 
to all other HR HPV types—individually or combined—has repeatedly been documented in 
large, well-designed international longitudinal screening studies.
16-18
   In fact, approximately 
                                                            






40% of females who are HPV 16 persistent (repeatedly testing positive) will develop high-grade 
CIN within five years.
19
   
 The remaining 20 non-oncogenic HPV types
2
 which infect genital tissue are considered 
to be LR.
20
  LR HPV types 6 and 11 are associated with 90% of penile, vaginal, and anal warts.
21
 
In the 1999-2004 National Health and Nutrition Examination Survey (NHANES), 7.2% of 
females and 4% of males documented ever being diagnosed with genital warts (GW).
22
  Another 
large population-based European study documented a higher rate: 10.6% of approximately 
70,000 females sampled (aged 18 to 45 years) were reported to have a previous diagnosis of 
GW.
23
 GWs are easily treatable in an out-patient setting.  However, the psychological burden 




HPV Vaccination  
 There are currently three U.S. Food and Drug Administration (FDA)-approved, 
commercially available HPV prophylactic vaccines, Merck & Co.’s quadrivalent Gardasil and 
nonavalent Gardasil-9, and GlaxoSmithKline’s Cervarix.  Gardasil, Cervarix, and Gardasil-9 
were licensed in 2006, 2009, and 2014, respectively.  As per recommendations from the 
Advisory Committee on Immunization Practices (ACIP), HPV vaccination can be administered 
to girls 11 or 12 years of age with catch-up through age 26.
28,29
   In late-2009, Merck’s Gardasil 




                                                            





 Because Gardasil is a quadrivalent vaccine developed to protect against HPV types 16 
and 18 as well as types 6 and 11, it is indicated for the prevention of cervical cancer, 
precancerous cervical lesions, vulvar, vaginal, and anal cancers, and genital warts in females. 
Cervarix, however, is a bivalent vaccine targeted to protect against HPV types 16 and 18 and is 
thus indicated solely for the prevention of cervical cancer and precancerous cervical lesions in 
females.  In 2011, ACIP modified its recommendations of Gardasil for use in boys aged 11-12, 
with catch-up vaccination from 13 to 26 years, for the prevention of genital warts,  anal cancer 
and precancerous lesions (anal intraepithelial neoplasia [AIN]).
31,32
   The administration of both 
vaccines is identical; they are given in three doses at 1, 2, and 6 months. 
 Vaccine efficacy in Gardasil’s pivotal phase III randomized placebo controlled study for 
prevention of CIN 2/3, adenocarcinoma in situ, or cervical cancer related to HPV 16 or 18 was 
98% in the per-protocol susceptible population and 44% in an intention-to-treat population of all 
females who had undergone randomization (including those with and without previous HPV 
infection).
33
  For Cervarix, the vaccine efficacy for a primary endpoint of HPV type 16 or 18, 
CIN 2/3, or adenocarcinoma in situ (CIN2+) documented in the pivotal phase III randomized 
placebo controlled study was 98.1%.
34
 
 Clinical trials employing Gardasil have also documented excellent vaccine efficacy in 
preventing GWs. One study in females
35
 documented 95% vaccine efficacy, while another in 
males
36
 observed 90% efficacy for preventing GWs. 
 In December 2014, Gardasil-9 became the most recent HPV vaccine approved by the 
FDA for use in females and males.  It is a nonavalent vaccine, effective against nine HPV 







   The pivotal study compared the original Gardasil to Gardasil-9 in 14,000 females 
aged 16 to 26 years that were followed up to 54 months.   Noninferiority was achieved for HPV 
6, 11, 16, and 18, and efficacy against persistent HPV infection and/or CIN 2+ caused by HPV 




HPV vaccination and evidence of cross-protection  
Cross-protection (decreased prevalence) of five HR non-vaccine HPV types in the alpha-
9 species (i.e., HPV 31, 33, 35, 52, and 58) was observed in the phase III pivotal studies of both 
HPV vaccines.
29,34,39-41
  Because Cervarix is formulated with an adjuvant, cross-protection on 
non-vaccine HR types was expected.  In analyzing data submitted by GlaxoSmithKline from its 
new drug application (NDA) for Cervarix, the FDA noted that in PATRICIA, the pivotal study, 
vaccine efficacy against CIN2+ due to any of 12 non-vaccine oncogenic types (HPV types 31, 
33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) was 37.4%.  Moreover, efficacy against HPV 31-
related CIN2+ was deemed to be 89.4%.
29
  
 Documentation of non-vaccine-targeted HR HPV cross-protection from the receipt of  
Gardasil in its two phase III pivotal trials (FUTURE I and FUTURE II) was recently published.
39
  
In the pre-specified analysis, HPV genotypic cross-protection was also detected when combining 
all five HPV non-vaccine HR genotypes of the alpha 9 species (vaccine efficacy = 35.4%). 
Although the study was not powered to detect differences in individual genotypes, a statistically 






HPV vaccination and the prospect of future HPV-type replacement  
 The concern that a new ecological niche could be created by a reduction in the prevalence 
of HPV genotypes targeted by the vaccines (i.e., HPV 16 and 18) is not without historic 
precedent.  In the late 1990s and early 2000s, there was documentation of significant increases in 
the prevalence of non-vaccine serotypes that occurred after the wide-spread introduction of a 
heptavalent conjugate pneumococcal vaccine and a Bordetella pertussis vaccine.
42-46
 
While it is an important subject of concern being discussed by the HPV vaccine research 
community,
47,48
 there is no evidence of HPV type replacement in any of the pre-licensure HPV 
vaccine clinical trials to date.  The recent approval of Gardasil-9 with its nonavalent structure has 
quelled concerns over type-replacement, however, it is important to remember over 200 million 




HPV Vaccine Coverage in the U.S., Europe and Australia 
U.S.  
 From 2006-2011, U.S. HPV vaccine coverage steadily increased to a 53% completion 
rate of >1 doses in females aged 13-17.
50
   However, the rate of coverage flatlined to 53.8% in 
2011, and, in fact, a downward trend in coverage of >3 doses was noted between 2011 and 2012 
(34.8% vs. 33.4%).
51
   This setback to increase HPV vaccine uptake in females in the U.S. was 
met with great consternation from CDC leadership.
52
   For boys, the CDC reported that 8.3% 
received >1 vaccine dose in 2011.  However, the data on U.S. male vaccine coverage are 








 Published European HPV vaccine coverage data in females primarily exist from 
Scandinavian and Northern countries.  In Denmark, for example, where free HPV vaccination 
programs with Gardasil started in 2008-2009 for 12-year-old females and later those up to 15 
years, it is estimated that up to 85% of this population has received all three doses.
53
   In 
Germany, where federally-funded HPV vaccine programs exist for females aged 12-17 years, 
vaccination appears to take place much closer to the end of the recommended age where 




 Since 2007, Australia has funded a free national HPV vaccine initiative (employing 
Gardasil) for females aged 12-13 years.
56
  Later, two “catch-up” HPV vaccine initiatives took 
place between 2007–2009 for females aged 13-26 years. Vaccine coverage from the on-going 
free program is reportedly high, with >80% receiving one dose and >70% completing all three 
doses.
57
   While data is sparse for vaccine coverage from the 2-year catch-up program, one study 
documented that approximately 58% of females aged 15-26 years received at least one dose.
58
 
And, similar to the U.S., vaccine coverage data on males are incomplete.  
 
The Need for Early Impact of HPV Vaccination at the Population Level 
 It will be approximately 25 years until we can determine if HPV vaccination in females 
(and now in males) has had an impact in preventing ICC.
59
   Hence, the monitoring of early 





abnormalities, genital warts or HPV genotypes 16 and 18 at the population level—is an integral 
part of understanding the potential impact of HPV vaccination in the interim.  Thus, a systematic 
review of the literature which details changes in incidence or prevalence of HPV genotypes and 
clinical manifestations in the pre-vaccine era to that of the post-vaccine era is warranted.   
 
2.2 Methods 
Structure and Guidelines 
 This systematic review summarizes and synthesizes the population-based impact of HPV 
vaccination after licensure in 2006.  It includes studies that have examined changes in the 
prevalence of LR and HR HPV genotypes in females from the U.S., Europe, and Australia in the 
pre- and post-vaccination periods; and virologic changes in the incidence or prevalence of HPV 
clinically-related outcomes (e.g., genital warts or cervical intraepithelial neoplasia [CIN]).
 The review was undertaken per standardized practices as stipulated in the Preferred 




Information Sources and Search Criteria 
 Materials for this review were identified by searching three electronic databases: 
MEDLINE® (Ovid), PubMed® (National Library of Medicine [NLM]), and Scopus® (Elsevier).  
Rather than a detailed list of myriad search terms, a wide net was initially cast using two MeSH 
headings: “papillomavirus” and “vaccines” for any peer reviewed journal published after 1 





 Table 1.1 details the refinement for including articles in this review using MEDLINE®. 
After including “papillomavirus” and “vaccines,” the various terms were used to limit articles to 
only: 1) English language; 2) humans; 3) females; 4) 2007-2013; 5) not editorials or letters. To 
ensure capture of articles recently published in 2013 or published ahead of print, PubMed® was 
employed using the identical MeSH® headings and keywords, but only for articles published 
between 2012-2103. Finally, the same search of MeSH® headings and keywords was employed 
using the Scopus® database.  
 
Eligibility Criteria and Study Selection 
 All citations with abstracts identified in MEDLINE®, PubMed® and Scopus® databases 
were transferred to Endnote® 6.0 (Thomson Reuters).  After isolating and deleting duplicates in 
Endnote, a review of titles was conducted to assess for eligibility.  Journal articles for this review 
were deemed eligible if:  
 Both a pre- and post-vaccine period population were compared for virologic or HPV-
related clinical outcomes;  
 Physician-verified vaccination status data was available when vaccinated and 
unvaccinated patients were compared; 
 Historic controls came from the same patient population (e.g., same STD clinic); 
 None of pre- or post-vaccine patients populations were from previously conducted HPV 
vaccine RCTs (pharmaceutically sponsored or otherwise ); 
 GWs were  vaginal or anal;  
 HPV DNA data was collected in genotypic studies. 
 
 In cases of ambiguous titles, abstracts were consulted.  Upon selection from title review, 
abstracts were further analyzed for possibly relevant articles.  If articles were considered 





 Data from each article’s study were extracted using Excel.  Data were collected on: 1) 
location; 2) study design; 3) data source; 3) sample size; 4) demographics (sex and age); 5) 
patient population comparison/s; 6) measures used for calculating exposure, outcomes, and 
covariates; and 7) statistical analysis employed.  
Categorization of Articles 
 Articles were categorized into three tiers according to degree of outcome/vaccination 
impact (clinical vs. virological changes).  Tier 1 included those articles with the outcome cervical 
intraepithelial neoplasia; Tier 2 included those which described change in genital wart incidence; 
and Tier 3 was composed of studies detailing change of HPV vaccine-type genotypic prevalence 
(HPV 6, 11, 16, or 18).  
 
2.3 Results 
Selection of Journal Articles Included in Systematic Review 
 A total of 2,369 unduplicated journal articles were selected for title review. (Figure 1 
describes the flow of publications selected for review.) From these 2,369 articles, 327 abstracts 
were assessed.  Twenty-eight full manuscripts were read and analyzed from the 327 abstracts.  
Of these 28, 11 were excluded from final selection because: 1) subjects were HPV vaccine 
clinical trial participants (N=5); 2) no specified pre-vaccine era population was included (N=4); 
3) only HPV serology data collected (N=1); and 4) anal neoplasia was the only outcome data 






Categorization and characterization of articles  
 Table 2 summarizes all 17 studies of early HPV vaccine impact comparing pre- and post-
vaccine periods.  When categorized, two articles detailed changes in cervical abnormalities, such 
as CIN 
61,62
 (tier 1); 11 described change in genital wart incidence
27,54,63-71
  (tier 2); and four 
described change of HPV vaccine-type genotypic prevalence
72-75
 (tier 3).  The date of 
publications ranged from 2009 to 2013 with the first published on 16 October 2009 by Fairley 
and colleagues
66
 and the last on 1 October 2013 by Blomberg and colleagues.
65
   There were 
seven studies conducted in the U.S., five in Australia, four in Europe (two in Denmark, and one 
each in Sweden and Germany), and one in New Zealand. Twelve of the 17 studies employed an 
ecological study design.  Ten included males and females while seven enrolled only females.  
The number of participants enrolled in these studies—or where database information was used—
ranged from 225
72
 to over 6 million
54
.  Participants’ age varied greatly across studies: three 
enrolled and/or allowed all ages, while others had ages ranging from 10 to 79 years.  
 
Tier 1: Cervical abnormalities 
 The two studies evaluating vaccine impact on cervical abnormalities employed different 
study designs. One was an ecological study utilizing a state-based cervical screening register in 
~4 million Australian females in which no individual HPV vaccination data were available.
61
  
The U.S. study was government-sponsored and employed an “indirect cohort” design with 
monitoring system surveillance data on ~5,000 females (75% with vaccine data history).
62
  
While the Australian study had a set population from the pre- and post-vaccine period, the U.S. 





for the comparison of the outcome.  The outcome for both was CIN (high-or low-grade), 
however, the U.S. study was more exacting in that the lesions had to be DNA-positive for HPV 
16 or 18.  Results from the Australian and U.S. studies were similar: a decrease in high-grade 
CIN was observed between pre- and post-vaccine periods and unvaccinated and vaccinated 
females, respectively.  Of note, a significant decrease in CIN incidence was only documented in 
females <18 years old from the Australian study.    
 
Tier 2: Genital warts (GW) 
 Of the 11 GW studies, all but one employed an ecological study design.
65
   A Danish 
study used a retrospective cohort design with ~400,000 females from birth cohorts from 1989 to 
1999.  The Danish Civil Registration System was linked to the National Health Insurance 
Service Register and the Prescription Registry for exposure and outcome data.  Birth cohorts 
from 1989 to 1999 were selected because they had >10% HPV vaccination coverage (>1 dose). 
And unlike the 10 ecological studies which observed temporal trends in GW incidence or 
prevalence in a pre-vaccine versus post-vaccine period, the Danish cohort retrospectively studied 
vaccinated and unvaccinated girls and followed them for the occurrence of incident GWs.  GW 
data on vaccinated and unvaccinated girls was then compared using Cox proportional hazards 
models.  A statistically significant temporal trend in the relative risk of GWs was observed from 
oldest to youngest cohort. In fact, no incident GWs were documented in the youngest birth 
cohort.  
 Ten of the ecological GW studies measured incident infection while one study calculated 
annual prevalence.
67





 All studies stratified by age, however, there was substantial heterogeneity.  Some only 
stratified dichotomously by age (e.g., <20 vs. >20; <28 vs. >28)
66,70
 while others used multiples 
of 5-year age groups for their population.
54,67
   Regardless of how stratification was determined, 
it proved necessary as all GW studies noted the most marked decrease in females from the 
youngest age group. Two studies noted that the statistically significant GW decrease was no 
longer observed in females old than 20 years of age.
54,70
   Three found that females up to ages 
28-30 had lower incidence of GW in the post-vaccine period compared to the pre-vaccine 
period.
66,68,71
  And, one study found increased GW in females and males over 25 years of age.
64
   
 Data sources from the ten ecological studies come from two separate entities, sexual 
health clinics or large state or national patient databases or registries. Four were from sexual 
health clinics: three in Australia
27,66,71
 and one in New Zealand.
70
   Of the other six: two were in 
California (one private
67
 and one public
64
 insurance database); one was from the U.S. Defense 
Medical Surveillance System database of U.S. service members
69
;  and the remaining three were 






).  As expected, 
the number of patients in the databases and registries was substantial, from ~1.5 million
69
 to >6 
million.
54
    
 There was considerable standardization in outcome measures for how GW incidence or 
prevalence was obtained.  The four sexual health clinics specified that the diagnosis of GWs 
must be the first diagnosis and only in new patients.  The databases and registries used a 
composite of IDC-9 and ICD-10 codes (delineating genital viral warts) and a National Drug 
Code (NDC) for pharmacy-dispensed imiquimod or podofilox.  All ten ecological studies offered 
temporal trend analyses for outcome in GWs by year as well as between set pre- and post-





 As expected with ecological studies, individual HPV vaccination data was not available.  
Only one Australian study of patients from a sexual health clinic included prior HPV vaccination 
data on their subjects.
27
   The data, however, are only self-reported and no information was 
offered as to attempts at physician verification.  Nevertheless, the authors declare that their self-
reported data are similar to previously-published Australian vaccination coverage data.  
 Only one of the 11 GW studies did not include males in the sample.
65
   Table 2 separately 
analyzes data on males from the ten GW studies. Four did not specify the proportion of females 
and males enrolled.  Five of the ten studies including males documented a statistically significant 
decrease in GW incidence in their youngest age groups.
27,64,66,70,71
   Interestingly, three studies 
(all Australian) categorized and independently analyzed data on males if they had sex with 
women (MSW) or sex with men (MSM).
27,66,71
   In all three studies, it was only the MSW who 
were found to have a decrease in GW incidence. 
 
HPV infection 
 Four studies documented change in prevalence of HR HPV infection between pre- and 
post-vaccine periods.
72-75
  Three were conducted in the U.S., while the other was done in 
Australia.
75





conducted in the U.S. at university medical centers with females enrolled at either community 
health centers or STD clinics.  They used a previously-enrolled, pre-vaccine period cohort for 
their comparison group.  Neither had more than 800 patients.  The Australian study was similar 
in the fact that it used a repeat cross-sectional design collecting HPV DNA samples on two 







   The largest study by far employed an ecological study design.
74
   It was conducted 
by the CDC using its NHANES data from four 2-year cycles of HPV DNA vaginal swab samples 
(2003-2010). It comprised >8000 females aged 14-59 equally divided into pre- and post-vaccine 
periods who were analyzed by age groups (14-19; 20-24; 25-29; 30-39; 40-49; and 50-59 years 
old).  While the methods are virtually identical across all four surveys, the one significant 
difference was that the 2003-2004 and 2005-2006 surveys over-sampled females aged 14-19 
years (n=1,363) but did not for 2007-2008 and 2009-2010 (n=740).  No explanation is offered as 
to why the over-sampling of this age group was discontinued.   
 The upper-limit age in the three non-ecological studies was much lower than in the 
NHANES study.  One study
72
 enrolled females only up to 17 years of age, while the other two 
allowed females up to age 24-26 years.
73,75
  
 One of the four studies simply compared all HPV types and HR vaccine-type (HPV 16 & 
18)
72
 while the other three attempted to compare prevalence data on all HPV types (using the 
Hoffmann‑La Roche Linear Array® Assay), LR VT-HPV (6 & 11), HR VT-HPV, and non-VT-
HPV.  This larger comparison was done in order to determine if there was evidence of cross 
protection (decreased HPV prevalence) as well as possible type-replacement (increased HPV 
prevalence) of HR HPV types.  
 There was heterogeneity in collection of HPV vaccination history data.  The two smaller 
U.S. cohort studies had physician-verified data while the Australian and NHANES studies used 
self-reported vaccine history.    
 All four studies documented a statistically significant decrease in the primary endpoint of 





significant decrease in prevalence in HPV 16 and 18 between the pre- and post-vaccine periods 
was only documented in females aged 14-19 years (prevalence ratio: 0.50; 95% CI: 0.34-0.74 
[p<0.001]).  
 No study observed a statistically significant decrease in non-vaccine targeted HR HPV 
between the two periods, thus ruling out a finding of cross-protection between HPV 16 and 18 
and other genotypes that are part of the alpha 9 species.  With regard to the NHANES data, the 
fact that the pre-vaccine group was over-sampled with 1,363 females while the post-vaccine 
group was not and contained only 740 females may have underpowered the ability to document 
cross-protection in the 14-19 year old females.         
 Of the three studies which also looked for possible type-replacement with increased 
prevalence of non-vaccine targeted HR HPV from the alpha 9 species, only one of the cohort 
studies
73
 documented increased prevalence (60.7%–75.9%) in females who had been vaccinated 
compared to those who had not.   
 
2.4. Discussion 
 Results from all 17 studies analyzed in this systematic review demonstrate that at the 
population level, HPV vaccination which began in 2006 has had an immediate impact in 
reducing cervical abnormalities, GWs, and the prevalence of HPV vaccine-type infections.  
These results mimic the positive virologic and clinical outcomes of HPV vaccination that have 
been widely documented in numerous mathematical modeling studies.
76-90
  
 Of substantial importance, and bringing to realization specific results of modeling 
studies,
87,89,90







   HPV vaccination coverage for males in these studies (three from 
Australia, one from New Zealand, and the other from the U.S.) was never documented to be over 
5%.  One explanation for this finding is that vaccination of young females provided some form 
of herd immunity to young males.  The most salient finding which lends credence to the herd 
immunity hypothesis comes from the three Australian GW studies
27,66,71
 that categorized males 
based on their sexual preference for females or other males.  All three studies noted a statistically 
significant decrease in GWs in MSWs but not in MSMs.  
 This finding was not replicated in studies outside of Australia, as only the Australian 
studies distinguished between MSWs and MSMs and utilized data from sexual health clinics. 
The only other study whose participants came from a sexual health clinic did not ask nor classify 
males based on their sexual preference.
70
   And understandably, national health or insurance 
databases, which were used in the remaining seven GW studies, do not have such specified 
information on their patients.     
The field of researchers from various parts of the world conducting these surveillance 
studies is still quite small.  While 17 studies on the early impact of HPV vaccination at the 
population level were identified, only five of the papers had independent, non-overlapping 
masthead authors.
54,67-70
   The two Danish studies had the same last author from the Danish 
Cancer Society Research Center.
63,65
   Of the five Australian studies, there were only two 
separate groups of researchers.  Four of the seven U.S. studies were conducted and/or sponsored 
by the CDC’s Division of STD Prevention,
62,64,67,74
 and a fifth was done by the Department of 
Defense (DoD) with editorial assistance from one of the CDC’s leading HPV experts.
69
   The 










The debate of using incidence versus prevalence for “newly detected” HPV in ecological 
and cross-sectional studies has been discussed in the literature for many years.
3,91,92
   This is 
because without long-term follow-up from longitudinal studies of females at or before the time 
of sexual debut, it is impossible to distinguish whether newly detected HPV infection is, in fact, 
a new acquisition or merely a reactivation of latent infection.
93
   HPV infection is not a constant; 
it is dependent on the interval between tests.  In fact, no assay currently exists to identify 
past/cleared HPV infection, the duration of given infection, or if a particular HPV genotype is 
either new or a reinfection.  Likewise, clearance of HPV DNA, at least to the point of non-
detectability, in younger females, is common.  One longitudinal study
94
 documented that 60% of 
women with LR HPV cleared their infection within 10 months, while another study
95
 found that 
females cleared their infection at 12% per month.  
Measurement of GWs can be as unpredictable as HPV DNA. GWs are often the 
immediate clinical manifestation of incident HPV infection.
92
   Many studies have documented 
that GWs are known to spontaneously clear in the absence of treatment, most likely because of 
acquired cellular immune responses.
96-98
   Moreover, many individuals with genital warts—either 
raised (exophytic) or flat—are completely unaware of them.
99
  
Measurement error is likely in studies utilizing databases that document particular ICD 
codes and/or prescriptions for imiquimod or podofilox.  In fact, authors from one study analyzed 
admit that their administrative database used for detecting GWs before 2007 was “incomplete 
and unreliable."
64
   Interestingly, they never mention if or how it was fixed.  
There should also be a dose of skepticism in trusting the rate of GW diagnosis in the GW 





changed in various countries in the post-vaccine era or between HPV vaccinated and non-
vaccinated women?  In one of the GW studies which documented an increase in GWs in older 
women in the post-vaccine era, the authors question if that finding is not simply due to increased 
health care-seeking behavior as a result of heightened awareness of HPV and its clinical 
manifestations.
64
   With regard to clinicians who perform cervical cancer screenings in post-
vaccine era, it is uncertain if knowledge of a patient’s vaccine status leads them to more or less 
closely inspect for GWs during examination.   
Another flaw apparent in many of the GW studies was not differentiating Gardasil from 
Cervarix and claiming that HPV vaccination (as single entity) was reasonable for the observed 
decrease in GWs.  This is a small yet not insignificant issue when claiming the exposure, simply 
“HPV vaccination,” was responsible for the outcome, a temporal change in GWs.  Gardasil is the 
only vaccine which protects against HPV 6 and 11, the genotypes responsible for 90% of GWs. 
There is no biologic plausibility that Cervarix would alter GW prevalence.  Nevertheless, 
because Gardasil was approved in all countries represented in this analysis two years before 
Cervarix (~2007), it does make the exposure-outcome claim relevant for females vaccinated 
before 2009. In fact, researchers of the ecological study from Germany point out that ~90% of 
females have been vaccinated with Gardasil as opposed to Cervarix.
71
   Some researchers, 
however, contend that the current wide use of Cervarix will complicate future efforts to study the 
effect of HPV vaccination on GW prevalence.
67
  
 An issue worth exploring in these studies is whether sexual activity of young females has 
significantly decreased in the post-vaccine era, and, in turn, might be responsible for the decrease 
seen in all GWs studies.  A few researchers considered this in the discussion of their study 
results.  One from Sweden
68





females and males as well as increases in gonorrhea cases among both sexes.  Another researcher 
from one of the Australian studies revealed that at the Melbourne Sexual Health Centre, there 
was an absence of any significant change in initial diagnoses of genital herpes between 2004 and 




 All four HPV DNA infection studies included a population from the pre-vaccine era and 
one from the post-vaccine era.  Likewise, all attempted to delineate the number of females who 
were vaccinated versus not in the later time period.  In the two U.S. HPV DNA infection 
studies,
73,74
 the proportion of females receiving at least 1 vaccine dose was markedly different. In 
the Ohio cohort study, 59.2% received >1 dose compared to ~21% of similarly-aged females in 
the NHANES sample.  Interestingly, the vaccine rate in both studies differs from the U.S. 
national average of 48.7% as reported in the CDC-sponsored 2010 NIS-Teen Study.
51
   Neither 
study discusses the incongruity of vaccination coverage in their samples compared to the 
national average.    
 Three of the four HPV infection studies also compared prevalence between females 
reporting vaccination versus those not.
73-75
   All three studies included data on the self-reported 
number of doses of their participants, and defined “vaccinated” as receiving at least 1 dose. 
Grammatically this is correct, yet internationally, all guidelines stipulate that HPV vaccination 
must consist of a series of 3 injections over 6 months.  There are a few studies—those with 
serological endpoints of vaccine titers—which have suggested that one to two doses may be 
similarly as effective as all three doses.
100,101
   However, classifying both one dose and three 
doses together as “exposed” has been met with some misgivings in the literature.
102





Categorizing levels of vaccine exposure three ways, “not exposed,” “one or two doses,” or “all 
three doses,” would be more precise.  
 All HPV infection studies had enough power to demonstrate prevalence change in HPV 
infection when grouping vaccine-type genotypes 6, 11, 16, and 18. When attempting to 
document prevalence change in individual HPV types, some fell short. This was most 
pronounced in the NHANES study, which chose to compare individual genotypes only with their 
subset of 14-19 year old females.
74
   Indeed, individual comparisons were hampered because 
NHANES chose not to oversample this age group between 2007-2010 (n=738) as it had done 
between 2003-2006 (n=1363).  There was a relative standard error of >30% or less than 10 
observations for vaccine-type 11 and 18 as well as 5 for the 6 genotypes from the alpha-9 
species.   
A significant strength of this systematic review is its expansive approach of combining 
three different characteristics of early HPV vaccine impact: a decrease in cervical abnormalities, 
GWs, and genotypic prevalence. Except for a recently published brief summary on early HPV 
vaccine impact,
103
 this is the first systematic review on the subject which adhered to standardized 
practices as stipulated in the Preferred Reporting Items System for Systematic Reviews and 
Meta-Analyses (PRISMA).
60
 And as stipulated, there was external quality control of the data 
collection for this review.  As with all systematic reviews, it may be subject to publication bias in 
which early HPV impact studies with null or negative findings are possibly absent from the 
published literature.     
 Overall, this review found sufficient evidence to support an association of HPV 





the population levels.  Because it will be approximately 25 years until effectiveness of HPV 
vaccination—as evidenced by a marked decrease in the rate of ICC—can be demonstrated, these 
findings are essential to monitor the early and intermediate effects of HPV vaccination.  It should 
be reassuring that all 17 HPV studies from six countries analyzed in this sytematic review 
pointed in a positive direction; that vaccination is likely reducing the prevalance of HR HPV 
infections and that there has been an observed significant decrease in GWs and cervical 
abnormalities in populations where the vaccine has been availabe for ~7 years.  With the recently 
published data on the vaccines’s safety
51
 as well as the results from these 17 studies, 
pediatricians should make a concerted effort and take a more active role in discussing with 
parents the many benefits of HPV vaccination for their children.  
 
2.5 Tables and Figures 
  Table 2.1. Search criteria for MEDLINE®  (Ovid)  
  1.     exp Papillomavirus Vaccines/  
2.     hpv.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, 
protocol supplementary concept, rare disease supplementary concept, unique identifier] 
3.     human papilloma virus.mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier] 
4.     2 or 3  
5.     vaccin*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading 
word, protocol supplementary concept, rare disease supplementary concept, unique identifier]  
6.     4 and 5  
7.     1 or 6  
8.     limit 7 to (english language and female and humans and yr="2007 - 2013")  
9.     limit 8 to (editorial or letter)  






Figure 2.1. Diagram of the systematic review’s search strategy and results 

















Records identified through database searching: N=4,511 
 MEDLINE (OVID): N=2,332 
 Scopus (Elsevier): N= 2,018 
 PubMed [for only year 2013] (Ovid): N=161 
Duplicates analyses using EndNote® X6 
(Thomson Reuters) 
Final collection of papers 
for title review: N=2,369 
Abstracts assessed: N=327 
Full-text articles assessed for 
eligibility: N=28 
Excluded: N=299  
Studies included in qualitative 
synthesis: N=17 
Excluded: N=11 
 Subjects were HPV vaccine clinical trial 
participants: N=5 
 No specified pre-vaccine era population: 
N=4 
 Only HPV serology data collected: N=1 
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-Abbreviations: ref: reference; LGA: Low-grade [cervical] abnormalities; HGA:  High-grade [cervical] abnormalities;  CIN: cervical intraepithelial neoplasia;  GW: 
genital warts; IR: incidence rate; yr: year; y/o: year/s old; MSW: men who have sex with women; MSM: men who have sex with men; STD: sexually 
transmitted disease; vax: vaccine or vaccinated; VT: vaccine type (HPV 6, 11, 16, and 18); NS: non-statistically significant 
- Unless specified, pre-vaccine period is defined as any time before 31 December 2006 
- Unless specified, post-vaccine period is defined as any time after 1 January 2007 



























First author, year 
and ref#  
Country Time Periods 
Measured 
HPV Vax info 
on males? 
Categorized 
MSW or MSM? 
 
Outcome 
Baaudrup, 201363 Denmark 6/2006 – 
7/2011 
No No No significant change observed in any age group 
Bauer, 201264 U.S. 2007 - 2010 No No Prevalence decreased 19% in <21 y/o and 10% in 21-
25 y/o. No change observed in older age groups 
Donovan, 201127 Australia 1/2004-
12/2009 
No Yes From 7/2007-12/2009, incidence decreased from 
12.3% to 8.9% in MSW ≤26 y/o. No change was 
observed in MSM  
Fairley, 200966 Australia 1/2004-
12/2008 
No Yes In 2008, incidence decreased 5% in MSW. No 
change was observed in MSM 
Flagg, 201367 U.S. 1/2003 -  
12/2010 
No No Incidence increased for 15-39 y/o from 2003-2009, 
but then stable in 2010 
Leval, 201268 Sweden 2006-2010 No No No change was observed in any age group 
Mikolajczyk, 201354 Germany 2005-2008 No No No change was observed in any age group 
Nsouli-Maktabi, 201369 US 2000-2012 No No No change was observed from 2000-2009; incidence 







No No From 2007 - 2010, incidence decreased from 11.5% 
to 6.9% in <20 y/o 
Read, 201171 Australia  7/2004 – 
7/2011 
No Yes From 2007/2008–2010/2011, incidence decreased 
in MSW from 22.9% to 2.9% and from 16.1% to 
11.7% in 21-29 y/o. No change was observed in 
MSM 
-Abbreviations: ref: reference; y/o: year/s old; MSW: men who have sex with women; MSM: men who have sex with men; vax: vaccine or vaccinated 
- Unless specified, pre-vaccine period is defined as any time before 31 December 2006 
- Unless specified, post-vaccine period is defined as any after 1 January 2007 
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3.0 Chapter 3: 
  
Temporal trends in vaccine-type HPV genotypic prevalence  







 The present ecological study aims to investigate early virologic impact of HPV 
vaccination at the population level, namely temporal trends in vaccine-type HPV prevalence 
(HPV 6, 11, 16, and 18) before and after commercial availability of the quadrivalent vaccine, 
Gardasil, in 2006 in the U.S.  Data were drawn from more than 8,000 females aged 14-59 years 
enrolled between 2003-2010 in the NHANES HPV Vaginal Swab Surveys, a population-based, 
cross-sectional survey collecting HPV DNA specimens as well as socio-demographic and sexual 
behavior information.  Vaccine-type HPV genotypic prevalence was compared between females 
from the first two 2-year surveys (2003-2004 and 2005-2006; the “pre-vaccine period”) and 
females from the latter two 2-year surveys (2007-2008 and 2009-2010; the “post-vaccine 
period”) with specific analyses that stratified by age groups, states aggregated by highest and 
lowest vaccine coverage, and prior vaccination history.  “Modified Poisson” regression models 
with adjusted prevalence ratios were used to compare vaccine-type HPV prevalence between 
vaccine periods, and GEE regression models were employed to determine risk factors associated 
with vaccine-type HPV infection.  In the entire sample, prevalence of HPV 6 decreased between 
the two periods from 2.8% (95% CI: 2.2-3.4) to 1.8% (95% CI: 1.4-2.3).  Post-vaccine period 
females aged 14-19 years had a 73% and 51% reduction in LR and HR-HPV, respectively.  LR 
vaccine-type HPV prevalence was significantly less in vaccinated females compared to those 
unvaccinated.  No significant HPV prevalence difference was found between aggregated states 
with high versus low vaccine coverage.  These findings of decreased vaccine-type HPV 
prevalence in adolescent females should be used by public health professionals and pediatricians 
to help educate parents on the virologic activity and benefits of HPV vaccination for their 





3.1. Introduction  
 
 Human papillomavirus (HPV) is a small double-stranded DNA virus which infects 
cutaneous and mucosal epithelial cells.
1
   HPV-infected epithelial cells undergo terminal 
differentiation encoding eight open reading frames (ORFs) which are transcribed as polycystic 
mRNAs from a single DNA strand in order to override any normal regulation of differentiation 




 Of the approximately 120 HPV types that have been identified, 40 types sort into 15 
alpha species which infect the genital tract.
3
  These 40 HPV types are divided into two groups: 
high-risk (HR), also referred to as oncogenic or carcinogenic, and low-risk (LR). HR HPV 
genotypes have been etiologically linked to invasive cervical cancer (ICC)
4,5
 as well as vaginal, 
vulvar, penile, anal, and a subset of head and neck cancers.
6-10
  
 HPV is by far the most common sexually transmitted infection in the U.S. with 
approximately 6.2 million individuals infected yearly.
11
  Sexual activity—often within the first 6 
months of sexual debut—is the most pronounced risk factor for incident HPV infection in a 
female’s genital tract.
12,13
   HPV infection is age-dependent
14
 and detected most often in 
sexually-active females aged 20-24 years.
15
  
 ICC is the fourth most common cancer in U.S. females, with approximately 530,000 
cases diagnosed yearly.
16
   It is, however, the number one cancer in sub-Saharan African and 







   The World Health Organization (WHO) estimates that ICC is 
responsible for approximately 270,000 deaths worldwide—namely developing countries.
16
 
 The WHO’s International Agency for Research (IARC) has periodically classified and 
categorized  20 HPV genotypes in varying degrees of high-risk based on their potential 
carcinogenicity.
18-20
   Twelve genotypes, HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59, 
fall into Group 1 because of “sufficient evidence for cervical cancer;” HPV 68 is in Group 2A 
because it is “probably carcinogenic;” and the remaining seven genotypes, HPV 26, 53, 66, 67, 
70, 73, 82, are in Group 2B and considered “possibly carcinogenic.” 
20
    
 HPV 16 and 18 are overwhelmingly the HR types most strongly associated with 
approximately 70% of ICC.
21,22
   HPV 18, however, is most commonly detected in 
adenocarcinoma of the cervix.
22,23
   Approximately 40% of women who repeatedly test HPV 
positive (referred to as “persistent”) for type-16 will go on to develop high-grade (precancerous) 
cervical intraepithelial neoplasia (CIN).
24
   Moreover, there is a twelvefold increase in the risk of 
developing high-grade CIN in females with persistent HPV 16 and/or 18 infection compared to 
other HR HPV genotypes.
25
   Stage-3 CIN left untreated for many years can invade the base 
membrane of the epithelium causing frank cervical cancer.
26,27
  
 The 20 HPV types classified as LR HPV include HPV 6, 11, 32, 40, 42, 43, 44, 54, 55, 
61, 62, 64, 71, 72, 74, 81, 83, 84, 87, and 89.
28
   LR HPV 6 and 11 are associated with 90% of 
penile, vaginal, and anal warts.
29
   Genital warts (GWs) are often the immediate clinical 
manifestation of incident HPV infection.
30
   While GWs are easily treatable in an out-patient 
setting, the psychological burden caused by GWs, as well as the annual cost to health care 







 HPV prophylactic vaccination against HPV 6, 11, 16, and 18 has existed in the U.S. since 
2006.  Routine vaccination is recommended for all individuals aged 11 or 12 years. Catch–up 
vaccination is recommended for females and men who have sex with men aged 13 through 26 
years, and up to 21 years for men who have sex with women.
33-35
  The three U.S. Food and Drug 
Administration (FDA)-approved, commercially available vaccines differ in the number of 
specific HPV genotypes they prevent; however, all target HPV 16 and 18.  Pivotal studies of the 
three vaccines reported 90-98% vaccine efficacy on all endpoints (e.g., CIN 2/3 or GWs) and all 





 While long-term follow-up HPV vaccine efficacy data have been published on females 
enrolled in the initial industry-sponsored HPV vaccine studies, it exists only for those who 
received the vaccine, not placebo.
40,41
   Moreover, many of the initial vaccine randomized 
controlled trials (RCTs) enrolled a select female patient population due to strict inclusion and 
exclusion criteria, such as limiting the number of lifetime sexual partners and absence of HPV 
DNA at entry.  Thus, RCT data, regardless of follow-up duration, are unable to offer evidence of 
decreased HPV DNA prevalence at the population level between the pre- and post-vaccine eras. 
This is only possible from population-based, cross-sectional survey data of female HPV DNA 
prevalence before and after the advent of widespread HPV vaccination in 2006. 
 With a median age of 49 years for ICC in the U.S.,
42
 it will be approximately 25 years 
until significant clinical benefit of HPV vaccination—namely, a reduction in ICC incidence—
can be established.  Monitoring temporal trends in HR vaccine-type HPV 16 and 18 prevalence, 
as well as LR vaccine-type HPV 6 and 11, is the surest and most expeditious way of monitoring 
early vaccine impact at the population level.
43
   Marked decreases in the virologic prevalence of 





should consequentially result in declined incidence of GWs and cervical abnormalities, and over 
time, ICC. 
 The U.S. CDC-sponsored National Health and Nutrition Examination Survey (NHANES) 
has collected and analyzed HPV DNA vaginal swab samples on over 8,000 females between 
2003 and 2010.  NHANES vaginal swab survey data are ideal for capturing temporal trends in 
HPV genotypic prevalence.  Combining the first two 2-year surveys—2003-2004 and 2005-
2006—can serve as a pre-vaccine era period of unvaccinated/unexposed females, while 
combining the latter two 2-year surveys—2007-2008 and 2009-2010—serves as the post-vaccine 
era period representing the general U.S. female population during the first four years of 
widespread HPV vaccination.  No other population-based cross-sectional survey combines socio-
demographic information and sexual activity behavioral with laboratory data from both the pre- 
and post-vaccine eras.   
 Besides temporal trends analyses comparing HPV genotypic prevalence between the pre- 
and post-vaccine era NHANES, I will attempt to determine if there are geographical differences 
in vaccine-type HPV based on vaccine uptake.  I hypothesize in this analysis that the top-ten 
states with the highest vaccine coverage will show a larger decrease in vaccine-type HPV 
prevalence (HPV 16 and/or 18) in the post-vaccine period (2007-2010) than the bottom-ten states 
with the least vaccine coverage.  This would be another early indication that the vaccine is doing 
what it is supposed to.  This analysis is novel in that no published data exist on the correlation of 
HPV prevalence with HPV vaccination rates in the U.S.  
 Unlike previously published ecological studies examining temporal trends in vaccine-
type HPV genotypic prevalence in young females aged 14 to 19 years,
44-46





include females up to age 59 years.  I also examine whether socio-demographic characteristics 
such as age, race/ethnicity, and education as well as other known HPV risk factors, including 
sexual activity and marital status,
12-14,47
 confound prevalence estimate comparisons.   
 
3.2  Methods 
 
Study and collection of data  
NHANES is the largest of the four major CDC-sponsored National Center for Health Statistics 
(NCHS) data collection programs.  The initial basis for NCHS surveys was the National Health 
Survey Act (P.L.84–652), enacted on July 3, 1956.
48
   
 The NHANES program commenced in the early 1960s, conducting a series of surveys 
focusing on different population groups and health topics.  It became a continuous survey 
program in 1999 that focused on a variety of health and nutrition measurements of a nationally 
representative sample of approximately 20,000 persons each year.  NHANES obtains a 
nationally representative sample of non-institutionalized U.S. individuals by using a complex, 
stratified, multistage probability sample design with unequal probabilities.
49
   Adolescents, non-
Hispanic blacks, and Mexican Americans are oversampled in order to allow sufficient sizes for 
subgroup analysis. 
 HPV DNA testing for females was added to NHANES in its 2003-2004 survey.
47
   HPV 
DNA testing occurred on females aged 14-59 years with the use of self-collected vaginal swabs. 
Consenting participants have a household interview followed by a physical examination in a 





to a mobile home) which resemble a fully-functioning medical clinical with myriad diagnostic 
equipment (e.g., CT scan), and banks of computers for data entry.  They are situated in locations 
convenient for enrolled participants. 
 
Sample for analysis 
 In each of the four cycles (2003-2004; 2005-2006; 2007-2008; 2009-2010), the CDC’s 
NCHS enrolled approximately 2,500 females for its NHANES HPV Vaginal Swab Surveys. 
Final data available for HPV DNA analysis usually drops to 2,100 females for a number of 
reasons, including 1) refusal of examination in the MEC; 2) unwillingness to self-collect a 
cervicovaginal swab sample; and 3) inadequacy of samples for DNA typing.  Data from 9, 850 
females aged 14-59 years are available for my analysis from the four 2-year NHANES HPV 
Vaginal Swab Surveys. All data are publicly available for downloading on the CDC’s NHANES 
website, except for those pertaining to female minors aged 14-17 years.  Data on minors, termed 
“limited use data,” are only available for analyses after a research proposal has been approved by 
the NCHS.  
 
Specimen collection  
 The protocol detailing instructions and methods of specimen collection has been 
described elsewhere.
47
   In brief, self-collection of a cervicovaginal sample took place in private 
in the bathroom of a MEC.  Females were given a collection device that had a small foam swab 
on a plastic handle packaged in an individual resealable plastic sleeve (Catch-All Sample 
Collection Swabs Epicenter, Madison, WI).  Foam swabs were to be inserted into the vagina—





sleeve.  NHANES personnel collected the material and mailed it to a CDC laboratory for 




 DNA extractions were performed within one month of collecting samples employing a 
modified QIAmp Mini Kit.
47,50
  The extract (100 µL total volume) was either tested immediately 
or stored at –20C.  To serve as a contamination control, a water blank was processed through all 
steps of extraction for every 40 samples.  
 DNA from the vaginal swab was extracted using two assays, the Qiagen Hybrid Capture 
(HC2) and Roche Linear Array (LA).  HC2 is a nucleic acid hybridization microplate assay with 
signal amplification.  It uses chemiluminescence for the qualitative detection of eighteen types of 
HPV DNA in cervical specimens.  The HC2 dichotomously differentiates between the two HPV 
DNA groups: low-risk (LR) HPV Types: 6, 11, 42, 43, and 44; and high-risk (HR) HPV types: 
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68.  It is, however, unable to determine the 
“specific” HPV type present. 
 The Roche LA is based on HPV L1 consensus polymerase chain reaction (PCR) with 
biotinylated PGMY09/11 primer sets.  It also includes biotinylated β-globin primers as an 
internal control for sample amplification.  The primer mix amplifies essentially all HPV types 
that are found in the genital tract along with the human β-globin.
51
  All samples are hybridized to 
the typing strip which included probes for 37 HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 
45, 51, XR(52), 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83, 84, 





the FDA for commercial use in the U.S. It is, however, approved for commercial use in the 
European Union. 
 The 2003-2004 NHANES Vaginal Swab Survey initially analyzed specimens using the 
Roche prototype line blot assay.  The second and following NHANES Surveys discontinued the 
Roche prototype line blot assay and employed the Roche Linear Array Assay (LA).  Saved 
samples from the 2003-2004 Survey were re-analyzed with the Roche LA, thus allowing for 
analyses of four 2-year surveys using the same laboratory methods.  
 
Demographic and behavioral data of study subjects 
 Before all female participants aged 14-59 years enter the MEC to self-collect vaginal 
swab samples, household interviews are conducted to obtain demographic information, including 
age, race, ethnicity, education, and marital status.  Race and ethnicity were self-reported into 
categories, including non-Hispanic black, non-Hispanic white, and Mexican American.  Using 
audio computer-assisted self-interview (ACASI), participants self-reported sexual history 
information.  Sex was defined as vaginal, oral, or anal sex.  For those females aged 14 to 17 
years who reported sexual activity, additional questions about sexual behavior were asked, such 
as age at first sex and number of lifetime sex partners.  For the females aged 18 years or older 
who reported past sexual activity, they were asked additional questions on the number and 
gender of sex partners in the last 12 months, lifetime sex partners, and past history of sexually 








HPV prevalence data aggregated by state 
 To determine if there are geographical differences in vaccine-type HR HPV prevalence 
based on vaccine uptake, I compare the prevalence of HPV 16 and/or 18 in the top-10 states with 
the highest vaccination coverage with that of the bottom-10 states with the lowest vaccination 
coverage in the post-vaccine period (2007-2010).  To ascertain if the prevalence change in HPV 
16 and 18 genotypes in the post-vaccine era is novel, I compare the prevalence in the aggregated 
states from the first two 2-year pre-vaccine era surveys to serve as a baseline.  
 States have been categorized based on published data from the adolescent portion of the 
CDC-sponsored National Immunization Survey, NIS-Teen.
52
  NIS-Teen is considered the most 
accurate of all immunization surveys because of its use of physician verification.
53
  The top-10 
states have a median of 44.8% HPV vaccine coverage for all 3 doses while the bottom-10 states 
have a median of 22.5%.  The top-10 states in descending order of most HPV vaccine coverage 
are: Rhode Island; South Dakota; Massachusetts; Connecticut; Washington; Wisconsin; 
Nebraska; New Hampshire; Pennsylvania; Virginia.  The bottom-10 states in ascending order 
with least vaccine coverage are:  Idaho; Arkansas; Mississippi; Alabama; Utah; Georgia; 
Indiana; Florida; Alaska; Kansas. (See Figures 3.1a & 3.1b for details.)  
 
Categorization of confounding variables 
 Potential confounders to be included in the pre-vaccination/post-vaccination analyses are: 
1) age; 2) race/ethnicity; 3) education; 4) marital status; 5) ever having sex; 6) age at sexual 
debut; and 7) total number of lifetime male sexual partners.  Age is categorized as: 14-19 years; 





categorized as younger than 16 years of age, older than 16 years of age, or never having had sex. 
(See Table 3.1 for a detailed listing of variables and their categorizations.) 
 
Statistical Analysis 
 All analyses were conducted using NHANES 2003-2010 sample weights to account for 
the complex survey design and to provide unbiased estimates of HPV prevalence and predictors 
for the total US population.
54,55
   Four-year weights are provided and recommended by NHANES 
when combining two 2-year surveys.  Data already account for weighting and a complex sample 
design, where WTMEC4YR =  ½ x WTMEC2YR for a 4-year sample. 
 Since the sample weights in NHANES were employed to oversample certain groups in an 
attempt to match the demographics of the U.S., I adjusted for strata and cluster to create unbiased 
estimates of my standard errors (e.g., 95% confidence intervals and p-values).  The primary 
analyses compare vaccine-type HPV genotypic prevalence in females in the pre-vaccine period 
(2003-2006) and post-vaccine period (2007-2010) samples across the 50 U.S. states, with the 
latter being further stratified into two groups based on the aggregated ten states with the highest 
and least vaccination coverage in the post-vaccine era as per CDC-sponsored NIS-Teen Survey 
data.  
 Prevalence estimates of HPV DNA will be reported as percentages with 95% confidence 
intervals.  Confidence intervals for HPV type-specific prevalence were estimated using methods 
adopted by Korn and Graubarde for proportions with small expected number of positive counts 







 To assess for differences in proportions of females testing HPV DNA-positive, χ2 tests 
and student t-tests were used.  The student t-test assumes that the data has a normal distribution, 
and that the covariance is small.  The CDC’s National Center for Health Statistics (NCHS) 
encourages use of the student t-test for NHANES data to detect differences in health outcomes or 
risk factors between subpopulations, and it contends that NHANES data “do meet both 
assumptions” provided data are not divided into very small sub-domains.  To explore for 
confounding, bivariate analyses with demographic and behavioral characteristics were conducted 
using a survey design-adjusted Wald F test. 
 I employ “modified Poisson” regression, as outlined by Zou,
57
 to adjust comparisons of 
prevalence by socio-demographic characteristics and sexual activity behavior that were found to 
vary between the groups of females and report adjusted prevalence ratios (aPR).  Modified 
Poisson regression for binary outcomes in population surveys provides robust error variance 
estimation and creates 95% confidence intervals with the correct coverage.
58
   Moreover, the 
robust error variances can be attained by using the repeated statement along with the subject 
identifier even when there is only one observation per subject.  Statistical significance was tested 
at the level of P< .05.  Associations were considered significant if the P value for the 
Satterthwaite adjusted F test
59
 is <0.05, and those variables were retained in the main effects 
model.  The formula for Satterthwaite's  approximation for the degrees of freedom for the 
approximate t statistic is: df = [( (w1+w2)2 )/( ( [(w12)/(n1-1)]+[(w22)/(n2-1)] ) )].
60
  All 










3.3  Results 
 
Comparison of HPV Prevalence between 2003–2006 and 2007–2010 
 A total of 9,850 females between the ages of 14-59 years were included in the analyses: 
4,990 from the first two 2-year surveys of 2003-2004 and 2005-2006 (henceforth referred to as 
the pre-vaccine period) and 4,860 from the latter two 2-year surveys of 2007-2008 and 2009-
2010 (henceforth referred to as the post-vaccine period).  Table 3.2 documents the age 
distribution of females enrolled in the pre- and post-vaccine periods.  Due to NHANES’s 
discontinuation of over-sampling younger females after the 2005-2006 Vaginal Swab Survey, the 
most significant demographic difference between females in the two periods is the approximate 
50% reduction in the number of females aged 14-19 years.  In this age group, there were 1,660 
pre-vaccine period females compared to 887 in the post-vaccine period.  However, the weighted 
distribution of females in this age category is not significantly different: 13.4% compared to 
13.0%. 
 Table 3.3a details the difference in HPV prevalence among the entire sample of females 
between the pre- and post-vaccine periods.  No significant unadjusted or adjusted difference was 
observed for all HPV (37 HPV genotypes types combined), HPV vaccine types (HPV 6, 11, 16, 
and 18 combined), or HR HPV vaccine types (16 and/or 18).  LR vaccine-type (HPV 6 and/or 
11) prevalence decreased in the post-vaccine period from 2.8% to 1.7% with an unadjusted 
prevalence ratio (PR) of 0.63 (95% CI: 0.46-0.87).  After adjusting for socio-demographic 
variables and sexual behavior, this decreased prevalence no longer remained statistically 





 To ascertain if there was an increased or decreased trend in HR vaccine-type prevalence 
before the advent of HPV vaccination, the two 2-year surveys from the pre-vaccine period were 
compared.  As documented in Table 3.3b, no statistically significant difference in HR vaccine-
type prevalence was observed between the 2003-2004 and 2005-2006 surveys.  
  When stratified by age, as documented in Table 3.4, decrease in HPV genotypic 
prevalence was only observed in post-vaccine period females from the youngest age group.  In 
adolescents aged 14-19 years, all HPV decreased from 27.5% (95% CI: 24.7-30.4) to 21.5% 
(18.2-24.8) with a PR of 0.78; (95% CI: 0.66-0.94).  LR vaccine-type prevalence decreased by 
73%, from 8.1% (95% CI: 5.0-11.3) to 2.2% (0.79-3.6) with a PR of 0.27 (95% CI: 0.13-0.56). 
And, HR vaccine-type prevalence decreased by 51%, from 6.0% (95% CI: 4.5-7.5) to 2.9% (95% 
CI: 1.9-4.0) with a PR of 0.49 (95% CI: 0.32-0.76).  
 
Comparison of individual HPV genotypic weighted prevalence between vaccine periods 
 As documented in Tables 3.5a-3.5f, the only change in individual genotypic prevalence 
in the entire sample of females was a decrease of HPV 6 prevalence in the post vaccine period: 
2.8% (95% CI: 2.2-3.4) compared to 1.8% (95% CI: 1.4-2.3).  When stratified by age, decreased 
prevalence of individual vaccine-type genotypes was only observed in the youngest group of 
females aged 14-19 years.  In this age group, decreased prevalence was found for HPV 6 (5.3% 
vs. 1.6%) and HPV 16 (5.8% vs. 3.0%). There was a trend towards decrease prevalence in HPV 
18 (1.6% vs. 1.0%); however, with so few observations in this particular age group, 95% 








Weighted HPV prevalence among females ages 14-29 years according to vaccination status 
  Self-reported vaccine history data exists on 1,835 of females aged 14-29 years enrolled 
in the post-vaccine period NHANES Vaginal Swab Studies.  NHANES defines “vaccinated” as 
receiving >1 dose of either the bivalent or quadrivalent HPV vaccine.  As documented in Table 
3.6, an 85% reduction in vaccine-type LR HPV prevalence was observed in 14-29 year-old 
vaccinated females: 3.5% in the unvaccinated versus 0.5% in the vaccinated (PR = 0.15; 95% CI: 
0-0.51).  A greater than 50% reduction in vaccine-type HR HPV prevalence was documented in 
vaccinated females with a PR of 0.42 (95% CI 0-1.18); however, it was not statistically 
significant.  It is important to note that for both observations, the prevalence estimates had a 
relative standard error >30%, and thus, these results are considered unstable and should be 
interpreted with caution.  
 
Geographical analysis of HR HPV prevalence in states with high-and low-vaccine coverage  
 Figures 3.1a and 3.1b detail 2010 NIS-Teen Survey data of the top-10 states with the 
highest reported HPV vaccine uptake—defined as receiving all 3 recommended doses—and the 
bottom-10 states with the lowest reported vaccine coverage.  The top-10 states had a median 
44.8% coverage (range: 41.5%-55.1%), while the bottom-10 states had a median 22.5% coverage 
(range: 17.6%-25.1%).  
 The aggregated states were compared in the 4-year pre-vaccine period in order to 
determine baseline vaccine-type HR HPV prevalence before the advent of widespread HPV 





vaccine-type HR HPV prevalence in females residing in the top-10 states with the highest 
reported vaccine coverage: 5.7% versus 6.4% (p=0.68).  Table 3.7b documents that vaccine-type 
HR HPV prevalence decreased modestly in both sets of aggregated states in the post-vaccine 
period.  Nevertheless, the slight decrease observed in vaccine-type HR HPV prevalence in 
females residing in the top-10 compared to the bottom-10 states—4.5% compared to 5.9% 
(p=0.38)—did not reach statistical significance.    
 
Risk factors associated with vaccine-type HPV prevalence in all females from both periods 
 Tables 3.8a documents the demographic and sexual behavior variables which were 
associated with combined LR and HR vaccine-type HPV prevalence in all females from both the 
pre- and post-vaccine periods.  In the multi-level GEE model, increased risk of vaccine-type 
HPV was associated with younger age—observed in all categorized female age groups less than 
40 years; lower education status (e.g., less than high school graduate or only a high school 
graduate); and not being married, be it single, partnered, or widowed/divorced/separated.  While 
marital status is often associated with and/or viewed as a modest proxy for sexual behavior, none 
of the sexual behavior variables—ever having sex, age at sexual debut, or lifetime number of 
sexual partners—were significantly associated with increased risk of vaccine type HPV.  No 
variables in the GEE model were found to have a statistically significant association with 








3.4  Discussion 
 Substantial and statistically significant decreases in the prevalence of preventable 
vaccine-type HPV infections were observed in females under the age of 20 years between the 
pre- and post-vaccine periods from the NHANES Vaginal Swab Surveys.  From the entire 
sample of females aged 14-59 years, only trends in decreased HR and LR vaccine-type HPV 
infections were documented.  These decreases of vaccine-type HPV—namely HR HPV 16 and 
LR HPV 6—in the younger females confirm previously published ecological study data 
indicating decreased vaccine-type HPV prevalence after the advent and widespread use of HPV 
vaccination in U.S. and Australian females.
44-46
   Moreover, the observed decreases in vaccine-
type HPV prevalence at the population level validate results generated in the pivotal phase III 
trials of both the bivalent and quadrivalent vaccines
36,37
 as well as the numerous mathematical 
modeling studies assessing the virological impact of HPV vaccination.
62-65
  
 In analyzing vaccine-type HPV prevalence between the two periods in the youngest age 
group, the decrease in vaccine-type prevalence was most pronounced in females 18 and 19 years 
old.  In these older adolescents, combined HR vaccine-type prevalence declined approximately 
70%, and almost 80% in LR vaccine-type prevalence.   
 There were even sizable prevalence decreases in specific individual vaccine-type HPV 
genotypes in the youngest age group.  A 70% and ~50% decrease in prevalence was observed in 
HPV 6 and HPV 16, respectively.  Due to limited observations and a relative standard error of 
>30% in this age group, the substantial decrease observed in HPV 18 did not reach statistical 





  Limited self-reported data are available on the particulars of HPV vaccination status of 
females in the 2007-2008 and 2009-2010 NHANES HPV DNA Vaginal Swab Surveys.  Vaccine 
information, in the form of two questions—received the vaccine (yes or no) and number of 
doses—is the extent of the information from females in the Vaginal Swab surveys who  
answered the NHANES Immunization (IMQ_E and IMQ_F) questionnaire.   
 As expected, history of vaccination was inversely correlated with age: 34.1%, 15.8%, and 
7.4% of females aged 14-19, 20-24, and 25-29 years, respectively.  Of those reporting receipt of 
>1 dose, 62.5%, 43.2% and 45.7% said they received all 3 recommended doses.  The 34.1% rate 
of receiving >1 dose documented in the NHANES adolescents is considerably lower than the 
national average.  The physician-verified CDC-sponsored NIS-Teen Survey reported that 48.7% 
adolescent females received >1 HPV vaccine dose in 2010.
52
  
  Nevertheless, and unsurprisingly, the largest difference in vaccine-type HPV prevalence 
was observed when comparing females who received >1 vaccine dose to those unvaccinated.  
While the 58% reduction of vaccine-type HR HPV and 85% decrease in vaccine-type LR HPV 
in vaccinated females is impressive, only statistical significance was reached in the LR vaccine-
type comparison.  
 Such markedly reduced vaccine-type HPV prevalence in vaccinated versus unvaccinated 
females has been previously documented in two published ecological studies.
44,45
  Our analyses 
differ from two other ecological studies due to the inclusion of older females up to age 29 years. 
The 2013 NHANES analysis 
44
 included females aged 14-19 years, whereas the Australian study 





HPV vaccination compared to ~21% of similar-aged females in the NHANES Vaginal Swab 
Survey. 
 No significant difference in weighted socio-demographic variables or reported sexual 
behavior was observed at baseline between the pre- and post-vaccine period females.  In the 
multivariate analyses, younger age, lower education level, and not being married were 
significantly associated with increased vaccine-type HPV prevalence, and no risk factors were 
found to be protective of decreased prevalence.  These results differ from our multivariate model, 
as shown in Table 3.8c, of risk factors associated with all 37 HPV genotypes combined.  Here, 
non-white race, ever having sex, and multiple lifetime number of sexual partners were found to 
be statistically significantly associated with increased risk of all 37 HPV genotypes combined.    
 In numerous longitudinal studies, younger age—most likely because of its correlation 
with sexual partnership—has been associated with increased risk of HPV.
47,66,67
   Our finding 
that not being married is associated with increased risk of HPV confirms a number of previously 
published studies.
68-70
   Unlike many other analyses that have documented higher lifetime 
number of sexual partners as a distinct vaccine-type HPV risk factor,
12,47,67,71-75
 this categorized 
sexual behavior variable did not reach statistical significance in pre- and post-vaccine period 
females.  
 There are conflicting data that suggest non-white race is independently associated with 
LR and/or HR HPV DNA.  Our results confirm a previously published analysis which did not 
find an association between nonwhite race and vaccine-type HPV infection.
66
   It does, however, 
conflict with results from two studies documenting increased risk of HPV infection in non-
Hispanic black females.
75,76





 Our analyses do not suggest the possibility that a reduction in vaccine-type HPV 
genotypic prevalence was occurring in the pre-vaccine era.  When comparing vaccine-type HPV 
prevalence between 2003-2004 and 2005-2006, no statistically significant decrease or increase 
was observed.  This does conflict with the results from a recently published Australian study 
which observed a trend towards decreased prevalence in the latter years of the pre-vaccine era.
45
 
 We are uncertain as to why there was only a modest and insignificant difference in   
vaccine-type HR HPV prevalence between the aggregated top-10 and bottom-10 states in HPV 
vaccine coverage.  While data are available from the 2010 NIS-Teen Survey on vaccine coverage 
of the top-10 states and the bottom-10 states, the CDC’s NCHS does not allow information of 
exact geographic location (e.g., state) of study participants due to patient confidentiality 
concerns.  The smallest unit of analysis the NCHS allows is the 10-state aggregation with a 
proviso that participants simply “resided in one of the ten states.”  Thus, it remains unclear how 
well distributed the post-vaccine era females were geographically.   
 
Strengths & Limitations 
 A significant strength of these analyses comes from access to publicly available 
NHANES data with its many years of well-characterized sampling method protocols and quality-
control laboratory manuals.  NHANES use of weighting and over-sampling of African 
Americans, Asians, and Hispanics speaks to its rigorous inclusion of myriad U.S. and foreign-
born populations in order to achieve a nationally representative sample.  
 The HPV DNA Vaginal Swab Survey, like many others in NHANES, is unique in that it 
combines interviews, physical examinations, and specimen collection.  No other population-





along with risk factor information including socio-demographic information, lifestyle, and sexual 
behavior history.  
 An additional strength of the analyses is that it is the first reported comparison of 
individual and grouped vaccine-type HPV DNA genotypic prevalence in a wide age range of 
females from 14 to 59 years before and after the advent of HPV vaccination in 2006.  Likewise, 
this is the first reported geographic analysis of HPV prevalence to be conducted in the history of 
the NHANES Vaginal Swab Surveys.    
 There are also a number of limitations to these analyses.  By their nature, the use of 
population-level data rather than individual-level data in these ecological analyses hampered our 
ability to assess causation between exposure and outcome.  While there are specific data on HPV 
genotype prevalence from the pre- and post-vaccination periods, no concrete, physician-verified 
data exist to determine if these females in the latter period were actually vaccinated.  It is only 
self-report data.  
My geographical comparator groups—the top-10 and bottom-10 states in vaccine 
coverage—can be considered crude and somewhat arbitrary.  As noted, this was the lowest 
geographic unit of analysis the CDC’s NCHS would make available.  Nonetheless, the use of the 
CDC-sponsored NIS-Teen Survey for quantifying vaccine coverage by state is considered the 
most accurate of all immunization surveys because of its use of physician verification.
53
   
While NHANES strives to conduct its samples with rigor and has excellent laboratory 
quality control, there are no other evaluations in the general U.S. population using self-collected 
vaginal swabs that would have allowed for a direct comparison of past or present HPV DNA 





genotypes often clear in females in 6-12 months,
77
 this point prevalence is certain to 
underestimate cumulative incidence.  Moreover, the HPV DNA vaginal swab sampling only 
measures current infection and does not indicate past exposure (and thus clearance) to HPV. 
This, however, is neither the fault of NHANES sampling nor its laboratory assay.  No assay 
currently exists to identify past/cleared HPV infection, the duration of given infection, or if a 
particular HPV genotype is either new or a reinfection.   
Another limitation is the inability to control for confounding of vaccine uptake in males 
in the two 10-state comparison groups.  While Merck did receive an additional indication from 
the FDA for Gardasil to be administered to males aged 9-26 years in 2009, data from the 2011 
NIS-Teen Survey on HPV vaccination coverage in males documents a national average of only 
8.3% in boys aged 13-17 years.
78
   Of note, only 19 states reported HPV vaccination coverage in 
males to CDC’s 2011 NIS-Teen Survey.  With male HPV vaccine coverage extremely low in 
states and/or not reported, it was not feasible to control for male HPV vaccination.   
 
Public Health Significance 
 These analyses of temporal trends in vaccine-type HPV prevalence between the pre- and 
post-vaccine periods at the population level have obvious and important public health 
consequences.  It is, of course, too early to determine if HPV vaccination in females has had an 
impact in preventing ICC.  Healthy People 2020 states a goal of HPV vaccination is to “reduce 
the death rate from cancer of the uterine cervix below a target of 2.2 deaths/100,000 females 
(from a baseline of 2.4 per 100,000 in 2007).”
79
   Thus, the monitoring of early vaccine impact, 
namely a reduction of HPV genotypes 16 and 18 at the population level, is an integral part of the 





CDC’s assertion that observing early virological outcomes of the vaccines is a “critical aspect of 
monitoring its population impact.”
43
 
 The confirmation of marked reduction in HPV 16 in adolescent females will be useful on 
a public policy level in order to advocate for increased HPV vaccination coverage (and 
education) in the U.S. of both young females and males.  Since 2006, HPV vaccine uptake in 
adolescent females has steadily increased, however, at a much slower rate than expected with a 
U.S. average of ~53% completion of 3 doses in females aged 13-17 years during 2011.
78
   Low 
level of coverage cannot necessarily be attributed to cost as the CDC-sponsored Vaccine for 
Child (VFC) Program
3
 and Section 317 grants to states cover the expense for low-income 
families.  This knowledge of the vaccine’s potent activity at the population level in preventing 
HPV 16—the most common genotype associated with ICC as well as head and neck cancers—
will offer healthcare professionals further proof of the vaccine’s effectiveness.  Armed with this 
information, physicians need to help dissuade parents’ notion that HPV vaccination is “not 
necessary or needed.”
80
   Undoubtedly, greater vaccine uptake in females due to the 
understanding that the vaccine is doing what it’s meant to—preventing a cancer-causing virus—
will undoubtedly help normalize and increase HPV vaccine uptake in males to prevent anal, 




                                                            
3 The VFC program provides vaccines at no cost to doctors who serve eligible children. Children younger than 19 
years of age are eligible for VFC vaccines if they are Medicaid-eligible, American Indian or Alaska Native or have 






 We specifically documented that vaccine-type LR and HR HPV prevalence markedly 
decreased in females aged 14-19 years who are part of the recommended vaccination age group. 
The present research adds to the accumulating body of evidence that HPV vaccination in 
adolescent females has profound virologic activity in reducing vaccine-type HPV genotypic 
prevalence and the early clinical sequel of HPV infection.
44-46,81-86
   Further studies are needed to 
ascertain if the vaccination provides cross-protection against non-vaccine-targeted HR HPV 
genotypes, and if there is any evidence of HR HPV type-replacement.  Moreover, future 
ecological studies assessing temporal trends in vaccine-type HPV prevalence will need to include 
males.  If these studies can obtain physician-verified vaccine history of participants as well as 
male sexual behavior (e.g., heterosexual or homosexual), it may be possible to determine if 
decreased HPV prevalence is due, in part, to the effect of herd immunity.   
 Finally, with such strong mounting evidence of early virologic activity and a stellar safety 
profile, it is time for public health officials to strongly consider mandatory HPV vaccination for 
all school-aged females.  By using the model of Hepatitis B virus (HBV) vaccination programs, 
this will be the surest way to normalize HPV vaccination and prevent ICC and other HPV-
associated cancers at the population level.
87









3.5  Tables & Figures 
 
Table 3.1. Demographics: weighted distribution of  












14-19 years 13.4 13.0 
20-24 years 11.1 10.5 
25-29 years 9.8 10.9 
30-39 years 21.6 20.8 
40-49 years 24.5 23.5 
50-59 years 19.7 21.3 
Race/ethnicity 
Non-Hispanic white  67.7 64.6 
Non-Hispanic black 13.4 13.2 
Mexican American 8.7 9.2 
Other 10.1 13.0 
Educationa 
Less than high school  14.3 17.7 
High school graduate 23.3 21.5 
More than high school 62.4 60.7 
Marital status 
Married 49.6 54.7 
Widowed/divorced/separated 14.3 15.9 
Never married 28.7 20.8 
Living with partner 7.4 8.6 
Age at sexual 
debut 
<16 Years 39.4 40.6 
>16 Years 56.5 55.5 
Never had sex 4.2 3.9 
Total lifetime 
sex partners 
0 0.4 2.3 
1 18.0 16.3 
2 10.1 10.2 
3-5 28.7 29.4 














       Table 3.2. Age distribution of females between the pre- and post-vaccine periods 




14-19  years    N=1,660 N=887 
 
20–24 years N=551 N=513 
25–29 years N=523 N= 472 
 
30–39 years N=850 N= 1,034 
 
40–49 years N=795 N= 1,072 
 















Prevalence % (95% CI) 
 
      2003-2006                 2007-2010 
      (N=4990)                     (N=4860) 
 
Unadjusted 
Prevalence Ratioa (95% CI) 
  
Adjustedb 
Prevalence Ratioa (95% CI) 
Any HPVc  
37.0 (37.0-
38.7) 
35.0 (33.3-36.6) 0.95 (0.88-1.01) 0.96 (0.89-1.03) 
All vaccine 
typed 
7.7 (6.7-8.6) 6.8 (6.0-7.6) 0.89 (0.74-1.06) 0.99 (0.81-1.21) 
HR vaccine 
typee 
5.4 (4.6-6.2) 5.3 (4.6-6.1) 0.99 (0.81-1.22) Suppressed due to small cells 
LR vaccine 
typef 
2.8 (2.2-3.3) 1.7 (1.3-2.2) 0.63 (0.46-0.87) 0.81 (0.55-1.19) 
                          a Exponentiated prevalence ratios calculated using Zou’s “modified Poisson” regression model with a robust error variance57   
                         b Adjusted for age; race/ethnicity; education; marital status; age at sexual debut; and lifetime number of sexual partners 
                         c All 37 genotypes: HPV 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, XR(52), 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83, 84, 89, and IS39  
                        d  Vaccine-type HPV combine: HPV 6, 11, 16, and 18  
                        e  HR vaccine-type: HPV 16 and/or 18 
                        f LR vaccine-type: HPV 6 and/or 11 
                * P<0.05 
 
             Table 3.3b. HR HPV vaccine-type prevalence between the 1st & 2nd two-year surveys of the pre-vaccine period   
 
HR HPV vaccine-typea  
 
2003-2004 
Prevalence %  
n= 2387 
2004-2005 
Prevalence %  
n= 2603 
P-Value 
4.7  6.0  NS 
  
                             a 
HR vaccine type: HPV 16 and/or 18 
                            b 
Exponentiated prevalence ratio calculated using Zou’s “modified Poisson” regression model with a robust error variance
57









                   Table 3.4. Vaccine-type HPV prevalence in females stratified by age group  
 
                                     a Exponentiated prevalence ratios calculated using Zou’s “modified Poisson” regression model with a robust error variance57                                                
                                     b LR vaccine type: HPV 6 and/or 11 
                                     c HR vaccine type: HPV 16 and/or 18 
                        * P<0.05 
  
Age HPV Type  
2003-2006 
(% & 95% CI) 
2007-2010 




  n= 1660 n= 887   
LR vaccine-typeb* 8.1 (5.0-11.3) 2.2 (0.79-3.6) 0.27 (0.13-0.56) 
HR vaccine-typec* 6.0 (4.5-7.5) 2.9 (1.9-4.0) 0.49 (0.32-0.76) 
20-24 y/o 
  n=551 n=558   
LR vaccine-type 3.5 (1.6-5.4) 4.3 (2.3-6.3) 1.23 (0.60-2.51) 
HR vaccine-type  12.7 (9.0-16.3) 13.8 (10.0-17.5) 1.09 (0.73-1.61) 
25-29 y/o 
  n=523 n=540   
LR vaccine-type 3.4 (1.5-5.3) 3.1 (1.3-5.0) 0.92 (0.41-2.06) 
HR vaccine-type 6.9 (4.1-9.8) 9.1 (6.0-12.2) 1.32 (0.77-2.25) 
30-39 y/o 
  n=850 n=1,062   
LR vaccine-type 2.8 (1.4-4.2) 1.3 (0.54-2.0) 0.45 (0.21-0.97) 
HR vaccine-type 5.9 (3.9-7.8) 5.0 (3.6-6.4) 0.85 (0.55-1.31) 
40-49 y/o 
  n=795 n=1,164   
LR vaccine-type 1.6 (0.54-2.6) 1.2 (0.52-2.0) 0.78 (0.32-1.87) 
HR vaccine-type 3.0 (1.5-4.5) 4.0 (2.6-5.5) 1.35 (0.73-2.48) 
50-59 y/o 
  n=611 n=888   
LR vaccine-type 1.6 (0.59-2.7) 1.0 (0.21-1.8) 0.61 (0.22-1.67) 





Table 3.5a. Weighted prevalence of individual vaccine-type HPV genotypes among the            
entire sample from the NHANES HPV Vaginal Swab Surveys, 2003-2006 and 2007-2010 
              RSE: Relative Standard Error 
 
           Table 3.5b. Females aged 14-19 years 
             *p<.05; RSE: Relative Standard Error 
 









 2003-2006 (n=4,990)  2007-2010 (n=4,860) 
HPV Type Number  
positive 





 6 153 2.8 (2.2-3.4) 95 1.8 (1.4-2.3) 
11 20 0.3 (0.1-0.5) Suppressed: RSE >30% or <10 observations 
16 202 4.6 (3.8-5.4) 203 4.6 (3.9-5.4) 
18 88 1.8 (1.3-2.3) 92 1.6 (1.2-2.0) 
 2003-2006 (n=1,660)  2007-2010 (n=887) 
HPV Type Number  
positive 
Weighted % (95% CI) Number 
positive 
 
Weighted % (95% CI) 
 6* 79 5.3 (3.7-6.8) 20 1.6 (0.9-2.4) 
11 14 1.0 (0.3-1.7) Suppressed: RSE >30% or <10 observations 
16* 82 5.8 (4.2-7.5) 31 3.0 (1.8-4.1) 
18 33 1.6 (0.9-2.3) 10 1.0 (0.2-1.7) 
 2003-2006 (n=1,074)  2007-2010 (n=985) 
HPV Type Number 
positive 
Weighted % (95% CI) Number 
positive 
 
Weighted %  (95% CI) 
6 33 3.8 (2.9-5.3) 28  2.9 (1.7-4.0) 
11 1 0.2 (0.0-0.6) 8  0.5 (0.2-0.9) 
16 67 9.6 (7.1-12.2) 94 10.2 (7.9-12.4) 







          Table 3.5d. Females aged 30-39 years 
                RSE: Relative Standard Error 
 
           Table 3.5e. Females aged 40-49 years 
                RSE: Relative Standard Error 
 
 
           Table 3.5f. Females aged 50-59 years 
  
 2003-2006 (N=850)  2007-2010 (N=1,034) 
HPV Type Number   
Positive 
Weighted %   (95% CI) Number 
positive 
 
Weighted %  (95% CI) 
 6 18  3.0 (1.5-4.5) 18  1.7 (0.8-2.6) 
11 2  0.16 (0.4-0.7) Suppressed: RSE of >30% or <10 observations 
16 25  4.2 (2.3-6.0) 40  3.9 (2.5-5.3) 
18 21  2.8 (1.4-4.2) 24  1.9 (1.0-2.9) 
 2003-2006 (n=795)  2007-2010 (n=1,072) 
HPV Type Number   
Positive 
Weighted %   (95% CI) Number 
positive 
 
Weighted %  (95% CI) 
 6 12 1.4 (0.4-2.4) 16  1.0 (0.4-1.7) 
11 2 0.4 (0.0-1.0) Suppressed: RSE of >30% or <10 observations 
16 13  2.2 (0.8-3.5) 24 2.6 (1.4-3.9) 
18 8  1.2 (0.1-2.2) 26  1.6 (0.9-2.2) 
 2003-2006 (n=611)  2007-2010 (n=882) 
HPV Type Number   
Positive 
Weighted %   (95% CI) Number 
positive 
 
Weighted %  (95% CI) 
 6 11  1.6 (0.5-2.8) 12  1.1 (0.2-2.0) 
11 1  0.2 (0.0-0.5) 4  0.2 (0.0-0.4) 
16 15  2.2 (0.8-3.5) 14  1.3 (0.4-2.3) 







Table 3.6. Weighted vaccine-type HPV prevalence according to vaccination status 
among females ages 14-29 years from the post-vaccine period (2007-2010) 
HPV Type 
 
Prevalence (%)  
  
  Unvaccinated               Vaccinateda            
       N=1,423                          N=412 
 
 
PR (95% CI)b 
Any HPV (of 37 types) 33.9 37.2 1.10 (0.90-1.30) 
HR vaccine-type                
(HPV 16 and/or 18) 
9.3 3.9ⱡ 0.42 (0-1.18) 
LR vaccine-type             
(HPV 6 and/or 11) 
3.5 0.5ⱡ 0.15 (0-0.51)* 
Abbreviations: CI, confidence interval; PR, prevalence ratio; HR, high risk; LR, low risk; RSE, relative standard error. 
a 
Vaccination defined as a self-reported history of receiving ≥1 vaccine dose  
b 
Exponentiated prevalence ratios calculated using Zou’s “modified Poisson” regression model with a robust error variance,  













Table 3.7a. Weighted HR vaccine-type HPV prevalence in 2003-2006 among females who resided        
in one of the top-10 states with the highest HPV vaccine coverage compared to those who resided     
in one of the bottom-10 states with the lowest HPV vaccine coverage 
HPV Type  Top-10 states in vaccine 
coverageb (combined) 
 2003-2006  
 
Bottom-10 states in vaccine 






(HPV 16 and/or 18) 
 
 








According to 2010 NIS-Teen published data  
b 
Rhode Island; South Dakota; Massachusetts; Connecticut; Washington; Wisconsin; Nebraska; New Hampshire; Pennsylvania; Virginia 
c




Table 3.7b. Weighted HR vaccine-type HPV prevalence in 2007-2010 among females who resided         
in one of the top-10 states with the highest HPV vaccine coverage compared to those who resided     
in one of the bottom-10 states with the lowest HPV vaccine coverage 












HR vaccine-type (HPV 
























Table 3.8a. Multivariate GEE analysis of factors associated with LR and HR vaccine-type HPV    












20-24 years 2.80 (1.90-4.14) <0.0001 
25-29 years 2.01 (1.42-3.13) <0.001 
30-39 years 1.56 (1.06-2.29) 0.02 
40-49 years 1.21 (0.81-1.80) 0.36 
50-59 years Referent 
 
Race/ethnicity 
Non-Hispanic white  Referent 
 
Non-Hispanic black 1.03 (0.83-1.30) 0.79 
Mexican American 0.84 (0.63-1.12) 0.23 
Other 0.80 (0.57-1.12) 0.19 
Education 
Less than high school  1.48 (1.14-1.91) <0.01 
High school graduate 1.71 (1.35—2.16) <0.0001 
More than high school Referent  
Marital status 
Married Referent  
Widowed/divorced/separated 1.43 (1.04-1.97) 0.03 
Never married 2.28 (1.71-3.03) <0.0001 
Living with partner 2.13 (1.51-3.0) <0.0001 
Age at sexual 
debut 
Never had sex Referent  
<16 Years 5.46 (0.54-54.87) 0.15 
>16 Years 5.68 (0.57-56.96) 0.14 
Total lifetime 
sex partners 
0 Referent  
1 0.69 (0.19-2.46) 0.57 
2 1.42 (0.41-4.90) 0.57 
3-5 1.82 (0.55-5.98) 0.32 



















Table 3.8b. Multivariate GEE analysis of factors associated with any HPV infection among females 












20-24 years 1.32 (1.16-1.49) <.0001 
25-29 years 1.16 (1.02-1.32) 0.02 
30-39 years 1.08 (0.96-1.21) 0.12 
40-49 years 1.03 (0.92-1.16) 0.57 
50-59 years Referent  
Race/ethnicity 
Non-Hispanic white  Referent  
Non-Hispanic black 1.24 (1.15-1.33) <.0001 
Mexican American 1.26 (1.15-1.37) <.0001 
Other 1.16 (1.03-1.30) 0.01 
Educationa 
Less than high school  1.18 (1.09-1.29) <.0001 
High school graduate 1.24 (1.14-1.35) <.0001 
More than high school Referent  
Marital status 
Married Referent  
Widowed/divorced/separated 1.56 (1.42-1.71) <.0001 
Never married 1.43 (1.29-1.57) <.0001 
Living with partner 1.46 (1.30-1.64) <.0001 
Age at sexual 
debut 
Never had sex Referent  
<16 Years 3.10 (1.40-6.87) <0.01 
>16 Years 3.22 (1.45-7.11) <0.01 
Total lifetime 
sex partners 
0 Referent  
1 0.55 (0.33-0.91) 0.02 
2 0.97 (0.59-1.60) 0.91 
3-5 1.39 (0.86-2.23) 0.19 













Figure 3.1a. Top-10 states with the highest estimated HPV vaccination coverage                           
(all 3 doses) - NIS-Teen Survey, 2010                                          
 
 
Figure 3.1b. Bottom-10 States with the lowest estimated HPV vaccination coverage                     
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*P<0.05; Missing bars in 2007-2010 denote a relative standard error of >30% or <10 outcomes 















3.6  References 
 
1. Hebner CM, Laimins LA. Human papillomaviruses: Basic mechanisms of pathogenesis 
and oncogenicity. Rev Med Virol 2006;16:83-97. 
 
2. Stanley M. Immune responses to human papillomavirus. Vaccine 2006;24:S16-S22. 
 
3. International Agency for Research on Cancer. Monographs on the evaluation of 
carcinogenic risks to humans: human papillomaviruses. Lyon, France: World Health 
Organization, International Agency for Research on Cancer; 2007:1-636. 
4. Munoz N, Bosch FX, De Sanjose S, et al. The causal link between human papillomavirus 
and invasive cervical cancer: A population-based case-control study in Colombia and Spain. Int J 
Cancer 1992;52:743-9. 
 
5. Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary 
cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9. 
 
6. Hoots, BE, Palefsky, JM, Pimenta, JM, Smith, JS. Human papillomavirus type 
distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 2009; 124:2375-2383. 
 
7. Franceschi S, Muñoz N, Bosch XF, Snijders PJF, Walboomers JMM. Human 
papillomavirus and cancers of the upper aerodigestive tract: A review of epidemiological and 
experimental evidence. Cancer Epidemiol Biomarkers Prev 1996;5:567-75. 
 
8. Brandsma JL, Abramson AL. Association of papillomavirus with cancers of the head and 
neck. Arch Otolaryngol Head Neck Surg 1989;115:621-5. 
 
9. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between 
human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709-20. 
 
10. Frisch M, Fenger C, Van Den Brule AJC, et al. Variants of squamous cell carcinoma of 
the anal canal and perianal skin and their relation to human papillomaviruses. Cancer Research 
1999;59:753-7. 
 
11. Weinstock H, Berman S, Cates Jr W. Sexually transmitted diseases among American 
youth: incidence and prevalence estimates, 2000. Perspect Sex Repro H 2004;36:6-10. 
 
12. Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal 
papillomavirus infection in young women. N Engl J Med 1998;338:423-8. 
 
13. Winer RL, Lee SK, Hughes JP, et al. Genital human papillomavirus infection: Incidence 






14. Franceschi S, Herrero R, Clifford GM, et al. Variations in the age-specific curves of 
human papillomavirus prevalence in women worldwide. Int J Cancer 2006;119:2677-84. 
 
15. Markowitz LE, Sternberg M, Dunne EF, McQuillan G, Unger ER. Seroprevalence of 
human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition 
Examination Survey 2003-2004. J Infect Dis 2009;200:1059-67. 
 
16. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer incidence and 
mortality worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for 
Research on Cancer; 2013. (Accessed November 4, 2013, at http://globocan.iarc.fr.) 
 
17. Franceschi S, Denny L, Irwin KL, et al. Eurogin 2010 roadmap on cervical cancer 
prevention. Int J Cancer 2011;128:2765-74. 
 
18. Muñoz N, Bosch FX, De Sanjosé S, et al. Epidemiologic classification of human 
papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27. 
 
19. Cogliano V, Baan R, Straif K, et al. Carcinogenicity of human papillomaviruses. Lancet 
Oncol 2005;6:204. 
 
20. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens--Part B: biological 
agents. Lancet Oncol 2009;10:321-2. 
 
21. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in 
high-grade cervical lesions and cervical cancer: A meta-analysis. Br J Cancer 2003;89:101-5. 
 
22. de Sanjose S, Quint WGV, Alemany L, et al. Human papillomavirus genotype attribution 
in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 
2010;11:1048-56. 
 
23. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus 
types in invasive cervical cancer worldwide: A meta-analysis. Br J Cancer 2003;88:63-9. 
 
24. Schiffman M, Herrero R, Desalle R, et al. The carcinogenicity of human papillomavirus 
types reflects viral evolution. Virology 2005;337:76-84. 
 
25. Schlecht NF, Kulaga S, Robitaille J, et al. Persistent human papillomavirus infection as a 
predictor of cervical intraepithelial neoplasia. JAMA 2001;286:3106-14. 
 
26. Richart RM, Barron BA. A follow-up study of patients with cervical dysplasia. Am J 
Obstet Gynecol 1969;105:386-93. 
 
27. Hawes SE, Kiviat NB. Screening for cervical cancer. In: Holmes KK, Sparling FP, 







28. Jacobs MV, De Roda Husman AM, Van den Brule AJC, et al. Group-specific 
differentiation between high- and low-risk human papillomavirus genotypes by general primer-
mediated PCR and two cocktails of oligonucleotide probes. J Clin Microbiol 1995;33:901-5. 
 
29. Greer CE, Wheeler CM, Ladner MB, et al. Human papillomavirus (HPV) type 
distribution and serological response to HPV type 6 virus-like particles in patients with genital 
warts. J Clin Microbiol 1995;33:2058-63. 
 
30. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human 
papillomavirus lesions, after initial infection. J Infect Dis 2005;191:731-8. 
 
31. Pirotta M, Ung L, Stein A, et al. The psychosocial burden of human papillomavirus 
related disease and screening interventions. Sex Transm Infect 2009;85:508-13. 
 
32. Hu D, Goldie S. The economic burden of noncervical human papillomavirus disease in 
the United States. Am J Obstet Gynecol 2008;198:500.e1-.e7. 
 
33. Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination 
recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 
2014;63:1-30. 
 
34. Petrosky E, Bocchini JA, Hariri S, et al. Use of 9-valent human papillomavirus (HPV) 
vaccine: Updated hpv vaccination recommendations of the advisory committee on immunization 
practices. MMWR 2015;64:300-4. 
 
35. CDC. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for 
use in males and guidance from the advisory committee on immunization practices (ACIP). 
MMWR 2010;59:630-2. 
 
36. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against 
human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43. 
 
37. Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus (HPV)-16/18 
AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV 
types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 
2009;374:301-14. 
 
38. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine 
against HPV infection and disease in males. N Engl J Med 2011;364:401-11. 
 
39. Joura EA, Giuliano AR, Iversen O-E, et al. A 9-valent HPV vaccine against infection and 






40. Romanowski B, de Borba PC, Naud P. Sustained efficacy and immunogenicity of the 
human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised 
placebo-controlled trial up to 6.4 years. Lancet 2009;374:1975-85. 
 
41. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-
adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-
study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13:89-99. 
 
42. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2008. 
2011. National Cancer Institute. Bethesda, MD, 2011. (Accessed June 1, 2014, at 
http://seer.cancer.gov/csr/1975_2008/.) 
 
43. Hariri S, Markowitz L. Monitoring HPV vaccine impact: Early results and ongoing 
challenges. J Infect Dis 2012;206:1633-5. 
 
44. Markowitz LE, Hariri S, Lin C, et al. Reduction in Human Papillomavirus (HPV) 
Prevalence among young women following HPV vaccine introduction in the United States, 
National Health and Nutrition Examination Surveys, 2003–2010. J Infect Dis 2013; 208:385-
393. 
 
45. Tabrizi SN, Brotherton JML, Kaldor JM, et al. Fall in human papillomavirus prevalence 
following a national vaccination program. J Infect Dis 2012;206:1645-51. 
 
46. Kahn JA, Brown DR, Ding L, et al. Vaccine-type human papillomavirus and evidence of 
herd protection after vaccine introduction. Pediatrics 2012;130: e249-e256. 
 
47. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in 
the United States. JAMA 2007;297:813-9. 
 
48. DHHS. Third National Health and Nutrition Examination Survey, 1988-1994, NHANES 
III Human papillomavirus-16 antibody data file. In: Prevention CDC, ed. Hyattsville, MD, 2001. 
 
49. CDC. National Center for Health Statistics. NHANES 2003-2004. (Accessed June 2, 
2012, at http://www.cdc.gov/nchs/about/major /nhanes/nhanes.) 
 
50. Hariri S, Unger ER, Sternberg M, et al. Prevalence of genital human papillomavirus 
among females in the United States, the National Health and Nutrition Examination Survey, 
2003-2006. J Infect Dis 2011;204:566-73. 
 
51. Van Doorn LJ, Quint W, Kleter B, et al. Genotyping of human papillomavirus in liquid 
cytology cervical specimens by the PGMY line blot assay and the SPF 10 line probe assay. J 
Clin Microbiol 2002;40:979-83. 
 
52. Dorell C, Stokley S, Yankey D, Liang JL, Markowitz L. National and state vaccination 







53. Tiro JA, Saraiya M, Jain N, et al. Human papillomavirus and cervical cancer behavioral 
surveillance in the US. Cancer 2008;113:3013-30. 
 
54. NCHS. Analytic note regarding 2007-2010 survey design changes and combining data 
across other survey cycles. 2011. (Accessed February 7, 2013, at 
http://www.cdc.gov/nchs/data/nhanes/analyticnote_2007-2010.pdf.) 
 
55. NCHS. National Health and Nutrition Examination Survey, 2011–2012 [Overview]. . 
2013. (Accessed March 14, 2013, at http://www.cdc.gov/nchs/data/nhanes/nhanes_11_12/2011-
12_overview_brochure.pdf.) 
 
56. Korn EL, Graubard BI. Confidence intervals for proportions with small expected number 
of positive counts estimated from survey data. Surv Methodol 1998;24:193-201. 
 
57. Zou G. A modified poisson regression approach to prospective studies with binary data.  
Am J Epidemiol 2004;159:702-6. 
 
58. Fang J. Using SAS Procedures FREQ, GENMOD, LOGISTIC, and PHREG to estimate 
adjusted relative risks – a case study. SAS Global Forum 2011, 4–11 April 2011. Las Vegas: 
SAS Institute Inc.; 2011, 345-2011. 
 
59. Satterthwaite FE. Synthesis of variance. Psychometrika 1941;6:309-16. 
 
60. Freund RJ, Littell RC. SAS System for Regression. 1986 ed. Cary, NC: SAS Institute 
Inc.; 1986. 
 
61. SAS Institute Inc. SAS® 9.4 Guide to Software Updates. Cary, NC: SAS Institute Inc.; 
2013. 
 
62. Bogaards JA, Coupe VMH, Xiridou M, et al. Long-term impact of human papillomavirus 
vaccination on infection rates, cervical abnormalities, and cancer incidence. Epidemiology 
2011;22:505-15. 
 
63. Smith MA, Canfell K, Brotherton JM, Lew JB, Barnabas RV. The predicted impact of 
vaccination on human papillomavirus infections in Australia. Int J Cancer 2008;123:1854-63. 
 
64. Drolet M, Boily MC, Van de Velde N, Franco EL, Brisson M. Vaccinating girls and boys 
with different human papillomavirus vaccines: Can it optimise population-level effectiveness? 
PloS One 2013;8:e67072. 
 
65. Malagón T, Joumier V, Boily MC, et al. The impact of differential uptake of HPV 






66. Wiley DJ, Masongsong EV, Lu S, et al. Behavioral and sociodemographic risk factors for 
serological and DNA evidence of HPV6, 11, 16, 18 infections. Cancer Epidemiol 2012;36:e183-
e9. 
 
67. Bauer HM, Hildesheim A, Schiffman MH, et al. Determinants of genital human 
papillomavirus infection in low-risk women in Portland, Oregon. Sex Transm Dis 1993;20:274-
8. 
 
68. Kahn JA, Lan D, Kahn RS. Sociodemographic factors associated with high-risk human 
papillomavirus infection. Obstet Gynecol 2007;110:87-95. 
 
69. Kreimer AR, Struyf F, Del Rosario-Raymundo MR, et al. Efficacy of fewer than three 
doses of an HPV-16/18 AS04-adjuvanted vaccine: Combined analysis of data from the Costa 
Rica Vaccine and PATRICIA trials. Lancet Oncol 2015;16:775-86. 
 
70. Giuliano AR, Papenfuss M, Schneider A, Nour M, Hatch K. Risk factors for high-risk 
type human papillomavirus infection among Mexican-American women. Cancer Epidemiol 
Biomarkers Prev 1999;8:615-20. 
 
71. Wheeler CM, Parmenter CA, Hunt WC, et al. Determinants of genital human 
papillomavirus infection among cytologically normal women attending the University of New 
Mexico student health center. Sex Transm Dis 1993;20:286-9. 
 
72. Dempsey AF, Gebremariam A, Koutsky LA, Manhart L. Using risk factors to predict 
human papillomavirus infection: implications for targeted vaccination strategies in young adult 
women. Vaccine 2008;26:1111-7. 
 
73. Ferrera A, Velema JP, Figueroa M, et al. Co-factors related to the causal relationship 
between human papillomavirus and invasive cervical cancer in Honduras. Int J Epidemiol 
2000;29:817-25. 
 
74. Tarkowski TA, Koumans EH, Sawyer M, et al. Epidemiology of human papillomavirus 
infection and abnormal cytologic test results in an urban adolescent population. J Infect Dis 
2004;189:46-50. 
 
75. Stone KM, Karem KL, Sternberg MR, et al. Seroprevalence of human papillomavirus 
type 16 infection in the United States. J Infect Dis 2002;186:1396-402. 
 
76. Hariri S, Dunne EF, Sternberg M, et al. Seroepidemiology of human papillomavirus type 
11 in the United States: Results from the third national health and nutrition examination survey, 
1991-1994. Sex Transm Dis 2008;35:298-303. 
 
77. Giuliano AR, Harris R, Sedjo RL, et al. Incidence, prevalence, and clearance of type-







78. Dorell C, Stokley S, Yankey D, et al. National and state vaccination coverage among 
adolescents aged 13-17 years - United States, 2011. MMWR 2012;61:671-7. 
 
79. DHHS. Healthy people 2020: immunization and infectious disease. (Accessed April 4, 
2013, at http://www.healthypeople.gov/2020/topicsobjectives2020/pdfs/Immunization.pdf.) 
 
80. Garcini LM, Galvan T, Barnack-Tavlaris JL. The study of human papillomavirus (HPV) 
vaccine uptake from a parental perspective: a systematic review of observational studies in the 
United States. Vaccine 2012;30:4588-95. 
 
81. Brotherton JML, Fridman M, May CL, et al. Early effect of the HPV vaccination 
programme on cervical abnormalities in Victoria, Australia: An ecological study. Lancet 
2011;377:2058-92. 
 
82. Read TRH, Hocking JS, Chen MY, et al. The near disappearance of genital warts in 
young women 4 years after commencing a national human papillomavirus (HPV) vaccination 
programme. Sex Transm Infect 2011;87:544-7. 
 
83. Leval A, Herweijer E, Arnheim-Dahlstrom L, et al. Incidence of genital warts in Sweden 
before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis 
2012;206:860-6. 
 
84. Baandrup L, Blomberg M, Dehlendorff C, et al. Significant decrease in the incidence of 
genital warts in young Danish women after implementation of a national human papillomavirus 
vaccination program. Sex Transm Dis 2013;40:130-5. 
 
85. Bauer HM, Wright G, Chow J. Evidence of human papillomavirus vaccine effectiveness 
in reducing genital warts: An analysis of California public family planning administrative claims 
data, 2007-2010. Am J Public Health 2012;102:833-5. 
 
86. Powell SE, Hariri S, Steinau M, et al. Impact of human papillomavirus (HPV) 
vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine 
2012;31:109-13. 
 
87. Bosch FX, Tsu V, Vorsters A, Van Damme P, Kane MA. Reframing cervical cancer 
prevention. Expanding the field towards prevention of human papillomavirus infections and 












 4.0 Chapter 4:  
 








 The aim of the present ecological study is to explore for evidence of HPV genotypic 
cross-protection and type-replacement at the population level in the first four years after the 2006 
commercialization of the first-generation quadrivalent HPV vaccine, Gardasil.  It is necessary to 
determine if vaccinating against high-risk (HR) HPV 16 and 18, the two genotypes responsible 
for approximately 70% of invasive cervical cancer (ICC), confers additional virologic activity, 
such as the beneficial effect of preventing non-vaccine-targeted HR HPV genotypes (cross-
protection), or the deleterious effect of increasing prevalence of one or more phylogenetically 
related HR HPV genotypes (type-replacement).  Data were drawn from more than 8,000 females 
aged 14-59 years enrolled between 2003-2010 in the NHANES HPV Vaginal Swab Surveys, a 
population-based, cross-sectional survey collecting HPV DNA specimens as well as socio-
demographic and sexual behavior information.  Non-vaccine-targeted HR HPV genotypic 
prevalence was compared between females from the first two 2-year surveys (2003-2004 and 
2005-2006; the “pre-vaccine period”) and females from the latter two 2-year surveys (2007-2008 
and 2009-2010; the “post-vaccine period”) with specific analyses that stratified by age groups, 
states aggregated by highest and lowest vaccine coverage, and prior vaccination history.  
“Modified Poisson” regression models with adjusted prevalence ratios were used to compare 
vaccine-type prevalence between vaccine periods, and GEE regression models were employed to 
determine risk factors associated with non-vaccine-targeted HR HPV infection.  Prevalence of 
non-vaccine-targeted HR HPV decreased between the two periods from 19.8% (95% CI: 17.3-
22.3) to 15.6% (95% CI: 12.6-18.5) with a PR=0.79 (95% CI: 0.63-0.99) in females aged 14-19 
years irrespective of vaccination status.  In vaccinated females compared to those unvaccinated, 





and genotypes from the alpha-7 species, PR=1.27 and 1.58, respectively.  No difference in non-
vaccine-targeted HR HPV prevalence was found between aggregated states with high versus low 
vaccine coverage.  These findings of decreased non-vaccine-targeted HR HPV, signifying cross-
protection, and increased genotypic prevalence in vaccinated females, suggesting type-
replacement, warrant confirmation though further study in females vaccinated with the first-
generation quadrivalent Gardasil vaccine. 
 
4.1.  Introduction 
  
Virologic aspects of HPV 
 
 Human papillomavirus (HPV) is a small double-stranded DNA virus which infects 
cutaneous and mucosal epithelial cells.
1
  HPV-infected epithelial cells undergo terminal 
differentiation encoding eight open reading frames (ORFs) which are transcribed as polycystic 
mRNAs from a single DNA strand in order to override any normal regulation of differentiation 




 Of the approximately 120 HPV types that have been identified, 40 types sort into 15 
alpha species which infect the genital tract.
3
  These 40 HPV types are divided into two groups: 
high-risk (HR), also referred to as oncogenic or carcinogenic, and low-risk (LR). HR HPV 
genotypes have been etiologically linked to invasive cervical cancer (ICC)
4,5
 as well as vaginal, 
vulvar, penile, anal, and a subset of head and neck cancers.
6-10
  LR HPV 6 and 11 are associated 
with 90% of penile, vaginal, and anal warts.
11
  Genital warts (GWs) are considered the most 







 The WHO’s International Agency for Research (IARC) has periodically classified and 
categorized  20 HPV genotypes in varying degrees of high-risk based on their potential 
carcinogenicity.
13-15
  Twelve genotypes, HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59, 
are in Group 1 because of “sufficient evidence for cervical cancer;” HPV 68 is in Group 2A 
because it is “probably carcinogenic;” and the remaining seven genotypes, HPV 26, 53, 66, 67, 
70, 73, 82, are in Group 2B and considered “possibly carcinogenic.” 
15
   
 These 20 HR genotypes taxonomically fall into 5 different alpha species: α5, α6, α7, α9 
and α11.
16
  HPV 16 and 18 are the HR genotypes most strongly associated with approximately 
70% of ICC,
17,18
 and belong to α9 and α7, respectively.  Five other HR HPV genotypes, HPV 31, 
33, 35, 52, and 58, exist in the α9 species, while four HR HPV genotypes, 39, 45, 59, and 68, 
belong to the α7 species.
16
  Of these nine HR HPV genotypes from the two species, strong 
evidence specifically points to HPV 31, 33, 45, 52 as the HR HPV genotypes—besides HPV 16 




Co-infection with multiple HR HPV types 
 
Co-infection with multiple HR HPV types (also referred to as clustering) from the α7 and 
α9 species is considered quite common in sexually active females.
19,20
  Many longitudinal studies 
have documented a large proportion of HPV infections are sustained by multiple genotypes.
19-22
  
In fact, having HPV 16 or 18 (or both) can itself be a risk factor for the development of being 
infected with other phylogenetically related HR HPV from the α7 and α9 species.  For example, 
it has been documented that females with incident HPV 16 or 18 infection have 5-7 times higher 
odds of acquiring a subsequent HPV 58 infection than those not infected with either HPV16 or 
18.
21





The true clinical significance of clustering remains unknown.  Strong evidence of the 
deleterious effect of clustering was documented in a 2009 longitudinal study of ~700 females. 
The females who were co-infected with HPV clusters of types 31-35-56 or 16-51-52 had greater 




Clinical sequel of HR HPV infection 
 Approximately 40% of women who repeatedly test HPV positive (referred to as 
“persistent”) for HPV 16 will go on to develop high-grade (precancerous) cervical intraepithelial 
neoplasia (CIN).
23
  Moreover, there is a twelvefold increase in the risk of developing high-grade 
CIN in females with persistent HPV 16 and/or 18 infection compared to other HR HPV 
genotypes.
24




 ICC is the fourth most common cancer in U.S. females, with approximately 530,000 
cases diagnosed yearly.
27
  It is, however, the number one cancer in sub-Saharan African and 
Southeast Asian females because high quality screening and early and effective treatment are 
sparse to non-existent.
28
  The World Health Organization (WHO) estimates that ICC is 




Vaccination against HPV 
  HPV prophylactic vaccination against HPV 6, 11, 16, and 18 has existed in the U.S. 
since 2006 beginning with the quadrivalent vaccine, Gardasil.  Routine HPV vaccination is 
recommended for all individuals aged 11 or 12 years, and catch-up vaccination for females aged 
13 through 26 years and males aged 13 through 21 years.
29-31





Drug Administration (FDA)-approved, commercially available HPV vaccines.  While they all 
differ in the number of specific HPV genotypes they prevent, all target HPV 16 and 18.  Pivotal 
studies of the three vaccines reported 90-98% vaccine efficacy on all endpoints (e.g., CIN 2/3 or 





 In December 2014, Gardasil-9 became the most recent HPV vaccine approved by the 
FDA for use in females and males.  It is a nonavalent vaccine, effective against nine HPV 
genotypes—the four from the original Gardasil, plus another five HR genotypes: HPV 31, 33, 
45, 52, and 58.
36
  The pivotal study compared the original Gardasil to Gardasil-9 in 14,000 
females aged 16 to 26 years that were followed up to 54 months.  Non-inferiority was achieved 
for HPV 6, 11, 16, and 18, and efficacy against persistent HPV infection and/or CIN 2+ caused 




HPV vaccination and genotypic cross-protection  
Cross-protection of five non-vaccine HR HPV genotypes in the α9 species (HPV 31, 33, 
35, 52, and 58) was observed in both the Cervarix and original Gardasil HPV vaccine phase III 
pivotal trials.
33,37-40
  Because Cervarix is formulated with an adjuvant, giving it high levels of 
cross-neutralizing antibodies, cross-protection of non-vaccine-targeted HR HPV genotypes was 
expected.  In analyzing data submitted by GlaxoSmithKline from its new drug application 
(NDA) for Cervarix, the FDA noted that in the pivotal study, PATRICIA, vaccine efficacy 
against CIN2+ due to a combination of 12 non-vaccine-targeted HR HPV genotypes (HPV 31, 
33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) was 37.4%.  Most importantly, efficacy against 







  In the original Gardasil phase III pivotal trials (FUTURE I and FUTURE II), cross-
protection was detected when combining all five non-vaccine-targeted HR HPV genotypes of the 
α9 species (vaccine efficacy = 35.4%).
37
  As with Cervarix, a statistically significant reduction in 
HPV 31 was observed.   
 
HPV vaccination and the prospect of future HPV-type replacement  
 The concern that a new ecological niche could be created by a reduction in the prevalence 
of HR HPV genotypes targeted by the vaccines (HPV 16 and 18) is not without historic 
precedent.  In the late 1990s and early 2000s, there was documentation of significant increases in 
the prevalence of non-vaccine serotypes that occurred after the wide-spread introduction of a 
heptavalent conjugate pneumococcal vaccine and a Bordetella pertussis vaccine.
41-45
 
 While it is an important subject of concern being discussed by the HPV vaccine research 
community,
46,47
 there was no evidence of HR HPV type replacement in any of the pre-licensure 
HPV vaccine clinical trials.   
 The U.S. CDC-sponsored National Health and Nutrition Examination Survey (NHANES) 
has collected and analyzed HPV DNA vaginal swab samples on over 8,000 females between 
2003 and 2010.  NHANES HPV DNA Vaginal Swab Survey data are ideal for capturing 
temporal trends in HPV genotypic prevalence.  Combining the first two 2-year surveys—2003-
2004 and 2005-2006—can serve as a pre-vaccine era period of unvaccinated/unexposed females, 
while combining the latter two 2-year surveys—2007-2008 and 2009-2010—serves as the post-
vaccine era period representing the general U.S. female population during the first four years of 
widespread HPV vaccination.  No other population-based cross-sectional survey has socio-





 An analysis of the HPV DNA Vaginal Swab Surveys was conducted to assess the 
relationship between vaccination and the beneficial outcome of cross-protection (decreased 
prevalence) of non-vaccine-targeted HR HPV genotypes from the α7 and α9 species.  This is the 
first study to examine for cross-protection of individual HR HPV genotypes from the α7 and α9 
species in multiple age groups.  This exploration is necessary to determine if the genotypic cross-
protection documented in the initial HPV vaccine clinical trials now exists at the population 
level. 
 In addition to an examination of HR HPV genotypic cross protection, I tested for type-
replacement—increased prevalence of combined non-vaccine-targeted HR HPV and those from 
the α-7 and α-9 species.  It might be too early to see evidence of viral type-replacement while 
still in the first decade of HPV vaccination.  Nevertheless, examining this effect at the population 
level is prudent as it would provide public health officials with a robust sense of urgency for 
continuing to recommend routine cervical cancer screening in HPV-vaccinated females.   
 Besides temporal trends analyses comparing non-vaccine-targeted HR HPV genotypic 
prevalence, I attempted to determine if there are geographical differences in genotypic 
prevalence in the post-vaccine era based on vaccine uptake.  The results of this geographical 
ecological analysis augment the pre- and post-vaccine prevalence comparison, offering 
additional HPV vaccine post-licensure indicator information of virologic cross-protection or 
type-replacement.  This analysis is novel in that no published data exist on the geographic 
correlation of U.S. HPV vaccination rates and genotypic prevalence.   
 Unlike previously published ecological studies examining temporal trends in vaccine-
type HPV genotypic prevalence in young females aged 14 to 19 years,
48-50





included females up to age 59 years.   I also examined whether socio-demographic 
characteristics such as age, race/ethnicity, and education as well as known HPV risk factors, 
including sexual activity and marital status,
51-54
 confound prevalence estimate comparisons.   
 
4.2  Methods 
Study and collection of data  
 NHANES is the largest of the four major CDC-sponsored National Center for Health 
Statistics (NCHS) data collection programs. The initial basis for NCHS surveys was the National 
Health Survey Act (P.L.84–652), enacted on July 3, 1956.
55
   
 The NHANES program commenced in the early 1960s, conducting a series of surveys 
focusing on different population groups and health topics.  It became a continuous survey 
program in 1999 that focused on a variety of health and nutrition measurements of a nationally 
representative sample of approximately 20,000 persons each year.  NHANES obtains a 
nationally representative sample of non-institutionalized US individuals by using a complex, 
stratified, multistage probability sample design with unequal probabilities.
56
  Adolescents, non-
Hispanic blacks, and Mexican Americans are oversampled in order to allow sufficient sizes for 
subgroup analysis. 




  HPV 
DNA testing occurred on females aged 14-59 years with the use of self-collected vaginal swabs. 
Consenting participants have a household interview followed by a physical examination in a 
mobile examination center (MEC). MECs are made up of four sideways-linked trailers (similar 





equipment (e.g., CT scan), and banks of computers for data entry.  They are situated in locations 
convenient for enrolled participants. 
 
Sample for analysis 
 In each of the four cycles (2003-2004; 2005-2006; 2007-2008; 2009-2010), the CDC’s 
NCHS enrolled approximately 2,500 females for its NHANES HPV Vaginal Swab Surveys. 
Final data available for HPV DNA analysis usually drops to 2,100 females for a number of 
reasons, including 1) refusal of examination in the MEC; 2) unwillingness to self-collect a 
cervicovaginal swab sample; and 3) inadequacy of samples for DNA typing.  Data from 9, 850 
females aged 14-59 years are available for my analysis from the four 2-year NHANES HPV 
Vaginal Swab Surveys. All data are publicly available for downloading on the CDC’s NHANES 
website, except for those pertaining to female minors aged 14-17 years.  Data on minors, termed 
“limited used data,” are only available for analyses after a research proposal has been approved 
by the NCHS.  
 Specimen collection  
 The protocol detailing instructions and methods of specimen collection has been 
described elsewhere.
51
  In brief, self-collection of a cervicovaginal sample took place in private 
in the bathroom of a MEC.  Females were given a collection device that had a small foam swab 
on a plastic handle packaged in an individual resealable plastic sleeve (Catch-All Sample 
Collection Swabs Epicenter, Madison, WI).  Foam swabs were to be inserted into the vagina—
similar to inserting a tampon—gently turned for 10 seconds and then replaced into the plastic 









 DNA extractions were performed within one month of collecting samples employing a 
modified QIAmp Mini Kit.
51,57
  The extract (100 µL total volume) was either tested immediately 
or stored at –20C.  To serve as a contamination control, a water blank was processed through all 
steps of extraction for every 40 samples.  
 DNA from the vaginal swab was extracted using two assays, the Qiagen Hybrid Capture 
(HC2) and Roche Linear Array (LA).  HC2 is a nucleic acid hybridization microplate assay with 
signal amplification.  It uses chemiluminescence for the qualitative detection of eighteen types of 
HPV DNA in cervical specimens.  The hc2 dichotomously differentiates between the two HPV 
DNA groups: low-risk (LR) HPV Types: 6, 11, 42, 43, and 44; and HR HPV types: 16, 18, 31, 
33, 35, 39, 45, 51, 52, 56, 58, 59, and 68.  It is, however, unable to determine the “specific” HPV 
genotype present. 
 The Roche LA is based on HPV L1 consensus polymerase chain reaction (PCR) with 
biotinylated PGMY09/11 primer sets. It also includes biotinylated β-globin primers as an internal 
control for sample amplification.  The primer mix amplifies essentially all HPV types that are 
found in the genital tract along with the human β-globin.
58
  All samples are hybridized to the 
typing strip which included probes for 37 HPV types: HPV 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 
42, 45, 51, XR(52), 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83, 





approved by the FDA for commercial use in the U.S.  It is, however, approved for commercial 
use in the European Union. 
 The 2003-2004 vaginal Swab Survey initially analyzed specimens using the Roche 
prototype line blot assay.  The second and following NHANES cycles discontinued the Roche 
prototype line blot assay and employed the Roche Linear Array Assay (LA).  Saved samples 
from the 2003-2004 Survey were re-analyzed with the Roche LA, thus allowing for analyses on 
four 2-year surveys using the same laboratory methods.  
 
Demographic and behavioral data of study subjects 
 Before all female participants aged 14-59 years enter the MEC to self-collect vaginal 
swab samples, household interviews are conducted to obtain demographic information, including 
age, race, ethnicity, education, and marital status.  Race and ethnicity were self-reported into 
categories, including non-Hispanic black, non-Hispanic white, and Mexican American.  Using 
audio computer-assisted self-interview (ACASI), participants self-reported sexual history 
information.  Sex was defined as vaginal, oral, or anal sex.  For those females aged 14-17 years 
who reported sexual activity, additional questions about sexual behavior were asked, such as age 
at first sex and number of lifetime partners.  For the females aged 18 years or older who reported 
past sexual activity, they were asked additional questions on the number and gender of sex 








Categorization of non-vaccine-targeted HR HPV 
 In all analyses, non-vaccine-targeted HR HPV is defined as a combination of the 
following 18 HPV genotypes: HPV 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 70, 
73, and 82.  Of these 18 non-vaccine-targeted HR HPV genotypes, nine are further categorized 
according to their familial relationship with the α7 species (HPV 39, 45, 59, and 68) or the α9 
species (HPV 31, 33, 35, 52, and 58).    
 
HPV prevalence data aggregated by state 
 In an attempt to determine if there is HPV cross-protection or type-replacement based on 
geographical differences in vaccine uptake, I compared the prevalence of non-vaccine-targeted 
HR HPV in the top-10 states with the highest vaccination coverage with that of the bottom-10 
states with the least vaccine coverage in the post-vaccine period (2007-2010).  To ascertain if the 
change in non-vaccine-targeted HR HPV genotypic prevalence is novel in the post-vaccine era, I 
compared the baseline prevalence in the aggregated states from the first two 2-year pre-vaccine 
era surveys.  
 States have been categorized based on published data from the adolescent portion of the 
CDC-sponsored National Immunization Survey, NIS-Teen.
59
  NIS-Teen is considered the most 
accurate of all immunization surveys because of its use of physician verification.
60
  The top-10 
states have a median of 44.8% HPV vaccine coverage for all 3 doses while the bottom-10 states 
have a median of 22.5%.  The top-10 states in descending order of most HPV vaccine coverage 
are: Rhode Island; South Dakota; Massachusetts; Connecticut; Washington; Wisconsin; 





with least vaccine coverage are:  Idaho; Arkansas; Mississippi; Alabama; Utah; Georgia; 
Indiana; Florida; Alaska; Kansas. (See Figures 4.2a & 4.2b for details).   
 
Categorization of confounding variables 
 Potential confounders to be included in the pre-vaccination/post-vaccination analyses are: 
1) age; 2) race/ethnicity; 3) education; 4) marital status; 5) ever having sex; 6) age at sexual 
debut; and 7) total number of lifetime male sex partners.  Age is categorized as: 14-19 years; 20-
24 years; 25-29 years; 30-39 years; 40-49 years; and 50-59 years.  Age at sexual debut is 
categorized as younger than 16 years of age, older than 16 years of age, or never having had sex. 
(See Table 4.2 for a detailed listing of variables and their categorizations.) 
 
Statistical Analysis 
 All analyses were conducted using NHANES 2003-2010 sample weights to account for 
the complex survey design and to provide unbiased estimates of HPV prevalence and predictors 
for the total US population.
61,62
  Four-year weights are provided and recommended by NHANES 
when combining two 2-year surveys.  Data already account for weighting and a complex sample 
design, where WTMEC4YR =  ½ x WTMEC2YR for a 4-year sample. 
 Since the sample weights in NHANES were employed to oversample certain groups in an 
attempt to match the demographics of the U.S., I adjusted for strata and cluster to create unbiased 
estimates of my standard errors (e.g., 95% confidence intervals and p-values).  The primary 
analyses compared non-vaccine-targeted HR HPV genotypic prevalence in females in the pre-
vaccine period (2003-2006) and post-vaccine period (2007-2010) samples across the 50 U.S. 





with the most vaccination coverage and least vaccination coverage as per CDC-sponsored NIS-
Teen Survey data.  
 Prevalence estimates of HPV DNA are reported as percentages with 95% confidence 
intervals.  Confidence intervals for HPV type-specific prevalence were estimated using methods 
adopted by Korn and Graubarde for proportions with small expected number of positive counts 
in complex multicenter survey data.
63
 
 To assess for differences in proportions of females testing HPV DNA-positive, χ2 tests 
and student t-tests were used.  The student t-test assumes that the data has a normal distribution, 
and that the covariance is small.  The CDC’s National Center for Health Statistics (NCHS) 
encourages use of the student t-test for NHANES data to detect differences in health outcomes or 
risk factors between subpopulations, and it contends that NHANES data “do meet both 
assumptions” provided data are not divided into very small sub-domains.  To explore for 
confounding, bivariate analyses with demographic and behavioral characteristics were conducted 
using a survey design-adjusted Wald F test. 
 I employed “modified Poisson” regression, as outlined by Zou,
64
 to adjust comparisons of 
prevalence by socio-demographic characteristics that were found to vary between the groups of 
females and report adjusted prevalence ratios (aPR).  Modified Poisson regression for binary 
outcomes in population surveys provides robust error variance estimation and creates 95% 
confidence intervals with the correct coverage.
65
  Moreover, the robust error variances can be 
attained by using the repeated statement along with the subject identifier even when there is only 
one observation per subject.  Statistical significance was tested at the level of P< 0.05. 







<0.05, and those variables were retained in the main effects model.  The formula for 
Satterthwaite's  approximation for the degrees of freedom for the approximate t statistic is: df = 
[( (w1+w2)2 )/( ( [(w12)/(n1-1)]+[(w22)/(n2-1)] ) )].
67





4.3  Results 
Comparison of non-vaccine-targeted HR HPV prevalence between 2003–2006 and 2007–2010 
 A total of 9,850 females between the ages of 14-59 years were included in the analyses: 
4,990 from the first two 2-year surveys of 2003-2004 and 2005-2006 (henceforth referred to as 
the pre-vaccine period) and 4,860 from the latter two 2-year surveys of 2007-2008 and 2009-
2010 (henceforth referred to as the post-vaccine period).  Table 4.3 documents the age 
distribution of females enrolled in the pre- and post-vaccine periods.  Due to NHANES’s 
discontinuation of over-sampling younger females after the 2005-2006 Vaginal Swab Survey, the 
most significant demographic difference between females in the two periods is the approximate 
50% reduction in the number of females aged 14-19 years.  The pre-vaccine period consisted of 
1,660 females compared to 887 in the post-vaccine period.  However, the weighted distribution 
of females in this age category is not significantly different: 13.4% compared to 13.0%. 
 Table 4.4 details the difference in all non-vaccine-targeted HR HPV and α7 and α9 
species prevalence among the entire sample of females between the pre- and post-vaccine 
periods.  No significant unadjusted or adjusted difference was observed in all non-vaccine-
targeted HR HPV and α7 species.  There was a decrease observed in α9 species prevalence in the 





adjusting for socio-demographic variables and sexual behavior, this decreased prevalence no 
longer remained statistically significant (aPR = 0.84; 95% CI: 0.69-1.03).   
  When stratified by age, as documented in Table 4.5, the only statistically significant 
prevalence decrease in the post-vaccine period was found for combined non-vaccine-targeted HR 
HPV in the youngest age group.  In adolescents aged 14-19 years, combined non-vaccine-
targeted HR HPV decreased from 19.8% (95% CI: 17.3-22.3) to 15.6% (12.6-18.5) with a PR of 
0.79; (95% CI: 0.63-0.99).  The only significant prevalence increase documented in all age 
groups was for combined non-vaccine-targeted HR HPV in females aged 25-29 years, from 
23.1% (95% CI: 18.5-27.7) to 32.3% (27.3-37.4) with a PR of 1.40 (95% CI: 1.09-1.80). 
 
Comparison of individual HPV genotypic weighted prevalence between vaccine periods by age 
 As documented in Table 4.6a-4.6f, there was no statistically significant change observed 
in grouped or individual HPV genotypic prevalence of α7 or α9 species between the two vaccine 
periods in any of the age groups.  
 
Weighted HPV prevalence among females ages 14-29 years according to vaccination status 
  Self-reported vaccine history data exists on 1,835 of females aged 14-29 years enrolled 
in the post-vaccine period NHANES Vaginal Swab Surveys.  NHANES defines “vaccinated” as 
receiving >1 dose of either the bivalent or quadrivalent HPV vaccine.  As documented in Table 
4.7, there was a statistically significant higher prevalence of combined non-vaccine-targeted 
HPV in vaccinated females compared to those not vaccinated.  Non-vaccine-targeted HPV 





females with a PR of 1.27 (95% CI: 1.02-1.52).  Alpha-7 species prevalence was 13.4% in 
vaccinated females compared to 8.5% in those unvaccinated (PR = 1.58; 95% CI: 1.15-2.01).  
There was a trend towards greater α9 species prevalence in vaccinated females: 10.8% versus 
7.6% (PR = 1.43; 95% CI: 0.97-1.90).  It is important to note that for these observations, the 
prevalence estimates had a relative standard error >30%, and thus, results are considered 
unstable and should be interpreted with caution.  
 
Geographical analysis of HR HPV prevalence in states with high-and low-vaccine coverage  
 Figures 4.1a and 4.1b detail 2010 NIS-Teen Survey data on the top-10 states with the 
highest reported HPV vaccine uptake—defined as receiving all 3 recommended doses—and the 
bottom-10 states with the lowest reported vaccine coverage.  The top-10 states had a median 
44.8% coverage (range: 41.5%-55.1%), while the bottom-10 states had a median 22.5% coverage 
(range: 17.6%-25.1%).  
 The aggregated states were compared in the 4-year pre-vaccine period in order to 
determine baseline non-vaccine-targeted HR HPV prevalence before the advent of HPV 
vaccination.  As detailed in Table 4.8a,  there was a small and insignificant non-vaccine-targeted 
HR HPV prevalence decrease during the pre-vaccine period in the top-10 states with the highest 
reported vaccine coverage: 20.1% versus 19.1% (p=0.73).  Table 4.8b documents non-vaccine-
targeted HR HPV prevalence between both sets of aggregated states in the post-vaccine period.  
During this period, no appreciable difference in non-vaccine-targeted HR HPV prevalence was 
observed.  Non-vaccine-targeted HR HPV prevalence in females residing in the top-10 states was 
22.1% compared to 21.9% for those residing in the bottom-10 states (p=0.96).  This observation 





areas where HPV vaccination is more common suggests no evidence of genotypic cross-
protection or type-replacement.        
 
Risk factors associated with non-vaccine-targeted HR HPV prevalence in females from both 
periods 
 Table 4.9a documents the socio-demographic and sexual behavior variables which were 
associated with combined non-vaccine-targeted HR HPV infection in all females from both the 
pre- and post-vaccine periods.  In the multi-level GEE model, increased risk of infection with 
non-vaccine-targeted HR HPV was associated with younger age—females aged 20-29 years; 
race/ethnicity (non-Hispanic black and Mexican America); lower education status (e.g., less than 
high school graduate or only a high school graduate); not being married, be it single, partnered, 
or widowed/divorced/separated; ever having sex (regardless of age at sexual debut); and having 
two or more lifetime sexual partners.  Interestingly, the only variable found to have a protective 
effect was having one lifetime sexual partner compared to the referent group of no lifetime 
sexual partners (risk ratio = 0.40; p-value <0.01).   
 Only socio-demographic variables were associated with increased risk of infection with 
HPV genotypes from the α7 and α9 species.  As detailed in Tables 4.9b and 4.9c, none of the 
sexual behavior variables conferred an increased risk or a protective effect.  And in contrast to 
the GEE model for non-vaccine-targeted HR HPV, non-Hispanic black race did not reach 








4.4  Discussion 
 We found a marked decrease in combined non-vaccine-targeted HR HPV prevalence in 
females under the age of 20 years between the pre- and post-vaccine periods from the NHANES 
Vaginal Swab Surveys.  The 21% decrease observed in non-vaccine-targeted HR HPV 
prevalence—irrespective of vaccination status—in 887 adolescent females from the post-vaccine 
period is highly suggestive of genotypic cross-protection.   
 This statistically significant decrease is novel and differs from three published cross-
sectional ecological studies with similar methods to ours.
48-50





 documented a sizable prevalence decrease of non-vaccine-targeted HR 
HPV in adolescent females; however, neither reached statistical significance.  In contrast, a 2012 
U.S. study found statistically significant increased prevalence of non-vaccine-targeted HR HPV 
in their entire sample of post-vaccine era females aged 13-26 years.
50
   
 It is important to note that when we narrowed our unit of analysis from the 18 combined 
non-vaccine-targeted HR HPV genotypes to their respective alpha species (α7 and α9) and 
further by individual genotypes, only modest, non-statistically significant decreases in 
prevalence were observed.  With such limited observations and small cells, this was 
understandably a power issue.  
 Of all individual non-vaccine-targeted HR HPV genotypes, we were expecting to observe 
a significant post-vaccine period decrease in HPV 33, a genotype phylogenetically related to 
HPV 16.  Marked decreased prevalence in HPV 33—suggesting cross-protection—was observed 




 phase 3 pivotal trials and more recently in an ecological 
study from Australia.
69





in our sample of post-vaccine period females; however, the CDC’s NCHS suppressed results in 
the dataset because of <10 observations and a relative standard >30%.  Results in the dataset 
were also suppressed for HPV 45 prevalence in post-vaccine period females.    
 Limited self-reported data are available on the particulars of HPV vaccination status of 
females in the 2007-2008 and 2009-2010 NHANES HPV DNA Vaginal Swab Surveys.  Vaccine 
information, in the form of two questions—received the vaccine (yes or no) and number of 
doses—is the extent of the information from females in the Vaginal Swab Surveys who  
answered the NHANES Immunization (IMQ_E and IMQ_F) questionnaire.   
 As expected, history of vaccination was inversely correlated with age: 34.1%, 15.8%, and 
7.4% of females aged 14-19, 20-24, and 25-29 years, respectively.  Of those reporting receipt of 
>1 dose, 62.5%, 43.2%, and 45.7% said they received all 3 recommended doses.  The 34.1% rate 
of receiving >1 dose documented in the NHANES adolescents is considerably lower than the 
national average.  The physician-verified CDC-sponsored NIS-Teen Survey reported that 48.7% 
adolescent females revived >1 HPV vaccine dose in 2010.
59
  
  The significant increased prevalence of combined non-vaccine-targeted HR HPV as well 
as α7-species in females who received >1 vaccine dose compared to those unvaccinated is 
suggestive of type-replacement.  These results confirm a smaller U.S. ecological study which 
found a 13.6% increase of combined non-vaccine-targeted HPV in vaccinated females who 
exclusively received Gardasil.
50





—observed decreased prevalence in a combination of HPV 31, 33, and 
35 in vaccinated females compared to those unvaccinated from the post-vaccine period.  Of note, 





 No significant difference in weighted socio-demographic variables or reported sexual 
behavior was observed at baseline between the pre- and post-vaccine period females.  In the GEE 
multivariate analyses of risk for combined non-vaccine-targeted HR HPV prevalence, all 
variables—younger age, lower education level, non-white race/ethnicity single marital status, 
and sexual activity—were  significantly associated with increased risk.  It is highly likely that 
both sexual behavior variables failed to reach statistical significance in the α7 and α9 species 
GEE models because of insufficient power to detect a difference.     
 In numerous longitudinal studies, younger age has been associated with increased risk of 
HPV.
51,71,72
  Our finding that single marital status is associated with increased risk of HPV 
confirms a number of previously published studies.
73-75
   
 There are conflicting data that suggest non-white race is independently associated with 
LR and/or HR HPV DNA.  Our results confirm results from two large studies documenting 
increased risk of HPV infection in non-Hispanic black females.
76,77
   
 We are uncertain as to why there was no appreciable difference in non-vaccine-targeted 
HR HPV prevalence between the aggregated top-10 and bottom-10 states in HPV vaccine 
coverage. While data are available from the 2010 NIS-Teen Survey on vaccine coverage of the 
top-10 states and the bottom-10 states, the CDC’s NCHS does not allow knowledge of exact 
geographic location (e.g., state) of study participants due to patient confidentiality concerns.  The 
smallest unit of analysis the NCHS allows is the 10-state aggregation and a proviso that 
participants simply “resided in one of the ten states.”  Thus, it remains unclear how well 






Strengths & Limitations 
 A significant strength of these analyses comes from access to publicly available 
NHANES data with its many years of well-characterized sampling method protocols and quality-
control laboratory manuals.  NHANES use of weighting and over-sampling of African 
Americans, Asians, and Hispanics speaks to its rigorous inclusion of myriad U.S. and foreign-
born populations in order to achieve a nationally representative sample.  
 The HPV DNA Vaginal Swab Survey, like many others in NHANES, is unique in that it 
combines interviews, physical examinations, and specimen collection.  No other population-
based survey in the U.S. or internationally has continuously collected HPV DNA genotypic data 
along with risk factor information including socio-demographic information, lifestyle, and sexual 
behavior history.  
 An additional strength of the analyses is that it is the first reported comparison of 
individual and grouped vaccine-type HPV DNA genotypic prevalence in a wide age range of 
females from 14 to 59 years before and after the advent of HPV vaccination in 2006.  Likewise, 
this is the first reported geographic analysis of HPV prevalence to be conducted in the history of 
the NHANES Vaginal Swab Surveys.    
 There are also a number of limitations to these analyses.  By their nature, the use of 
population-level data rather than individual-level data in these ecological analyses hampered our 
ability to assess causation between exposure and outcome.  While there are specific data on HPV 
genotype prevalence from the pre- and post-vaccination periods, no concrete, physician-verified 
data exists to determine if these females in the latter period were actually vaccinated.  It is only 





 My geographical comparator groups—the top-10 and bottom-10 states in vaccine 
coverage—can be considered crude and somewhat arbitrary.  As noted, this was the lowest 
geographic unit of analysis the CDC’s NCHS would make available.  Nonetheless, the use of the 
CDC-sponsored NIS-Teen Survey for quantifying vaccine coverage by state is considered the 
most accurate of all immunization surveys because of its use of physician verification.
60
   
While NHANES strives to conduct its samples with rigor and has excellent laboratory 
quality control, there are no other evaluations in the general U.S. population using self-collected 
vaginal swabs that would have allowed for a direct comparison of past or present HPV DNA 
prevalence.  Also, NHANES data only offer HPV DNA point prevalence.  Because HPV DNA 
genotypes often clear in females in 6-12 months,
78
 this point prevalence is certain to 
underestimate cumulative incidence.  Moreover, the HPV DNA vaginal swab sampling only 
measures current infection and does not indicate past exposure (and thus clearance) to HPV. 
This, however, is neither the fault of NHANES sampling nor its laboratory assay.  No assay 
currently exists to identify past/cleared HPV infection, the duration of given infection, or if a 
particular HPV genotype is either new or a reinfection.   
Another limitation is the inability to control for confounding of vaccine uptake in males 
in the two 10-state comparison groups.  While Merck did received an additional indication from 
the FDA for Gardasil to be administered to males aged 9-26 years in 2009, data from 2011 NIS-
Teen survey on HPV vaccination coverage in males documents a national average of only 8.3% 
in boys aged 13-17 years.
79
  Of note, only 19 states reported HPV vaccination coverage in males 
to CDC’s 2011 NIS-Teen survey.  With male HPV vaccine coverage extremely low in states 





Public Health Significance 
 Our analyses of temporal trends in non-vaccine-targeted HR HPV prevalence between 
the pre- and post-vaccine periods were in response to the CDC’s statement that observing early 




 It is, of course, too early to conclude if HPV vaccination in females has had an impact in 
preventing ICC at the population levels.  The marked decrease of HPV 16 and 18 observed in an 
assortment of international ecological studies comparing females from the pre- and post-vaccine 
period is reassuring.
48-50,69,70
  However, the suggestion of genotypic type-replacement with 
increased prevalence of non-vaccine-targeted HR HPV in our sample of vaccinated females—
which was found in previously published smaller ecological study—is concerning.
50
   
 In both studies, the genotypic type-replacement appears to be the result of receiving the 
first generation Gardasil.  The smaller 2012 ecological study enrolled women from clinics which 
exclusively administered Gardasil.  In our 2007-2010 post-vaccine period sample, we are certain 
that a vast majority of the females with a history of vaccination received Gardasil, essentially 
because Cervarix was not FDA-approved until October 2009. 
 The clinical significance of this possible genotypic type-replacement is unknown, 
especially with the extremely long latency period between persistent HR HPV infection, high-
grade CIN, and then ICC.  Likewise, genotypic type-replacement with non-vaccine-targeted HR 
HPV may be somewhat of a moot point with the advent of Gardasil-9.  For females—and 
possibly males—who are beginning to receive Gardasil-9 with its nonavalent structure, a 





redundant for individuals who have received over 200 million doses of the original Gardasil 
since 2006.
81
  Moreover, of the five additional genotypes, only one, HPV 45, is from the α7 
species in which we found the strongest evidence of grouped type-replacement.  Other HR HPV 
genotypes from the α7 species—HPV 39, 59, and 68—should now be a cause of concern.    
 
Conclusion 
 The present research adds to the accumulating body of evidence that HPV vaccination in 
adolescent females not only protects against HPV 16 and 18, but confers additional virologic    
activity that is both advantageous with cross-protection and deleterious with type-replacement.  
We specifically documented decreased prevalence of combined non-vaccine-targeted HR HPV 
in adolescent females irrespective of vaccination status, but found also a marked increase in the 
same HR HPV types in vaccinated females up to age 29 years.   
  Further study is warranted to confirm our observation of increased prevalence of non-
vaccine-targeted HR HPV in vaccinated females who received the original Gardasil.  HPV DNA 
cross-sectional studies could be undertaken in Australia and European countries with vaccine 
registries and cervical cancer screening programs.  If pre- and post-vaccine era cohorts do not 
exist, it is possible that pre-vaccine era HPV DNA prevalence data (or saved vaginal swab 
samples) could serve as historical controls.  It would also be prudent to ascertain if there is 
increase prevalence of non-vaccine-targeted HR HPV in colposcopy tissue samples in women 
with high-grade CIN.  
 Finally, this possibility of type-replacement with carcinogenetic HR HPV genotypes adds 





screening guidelines which state: “Women who have received the HPV vaccine should be 



















            4.5 Table & Figures 
 
             Table 4.1. Studies classifying HPV genotypes as “high risk” between 1995 and 2009  
       HPV Genotype 
 
Study   
16a,b 18a,c 26 31b 33b 35b 39c 45c 51 52b 53 56 58b 59c 66 67 68c 70 73 82 
Jacob, 199583 
 
                    
Gravitt, 199884 
 
                    
Davies, 200185 
 
                    
van den Brule,  
200286 
 
                    
Munoz, 200313 
 
                    
Cogliano, 200514 
 
                    
Smith, 200787 
 
                    
Bosch, 199588 
 
                    
Bouvard, 200915 
 
                    
                              a 
HR vaccine type: HPV 16 and/or 18 
                             b 
Alpha-9 species: HPV 16, 31, 33, 35, 52, and 58  
                             c 




                  Sufficient evidence                                                     Probably carcinogenic                                                   Possibly carcinogenic 
                  for cervical cancer  





Table 4.2. Demographics: weighted distribution of  













14-19 years 13.4 13.0 
20-24 years 11.1 10.5 
25-29 years 9.8 10.9 
30-39 years 21.6 20.8 
40-49 years 24.5 23.5 
50-59 years 19.7 21.3 
Race/ethnicity 
Non-Hispanic white  67.7 64.6 
Non-Hispanic black 13.4 13.2 
Mexican American 8.7 9.2 
Other 10.1 13.0 
Educationa 
Less than high school  14.3 17.7 
High school graduate 23.3 21.5 
More than high school 62.4 60.7 
Marital status 
Married 49.6 54.7 
Widowed/divorced/separated 14.3 15.9 
Never married 28.7 20.8 
Living with partner 7.4 8.6 
Age at sexual 
debut 
<16 Years 39.4 40.6 
>16 Years 56.5 55.5 
Never had sex 4.2 3.9 
Total lifetime 
sex partners 
0 0.4 2.3 
1 18.0 16.3 
2 10.1 10.2 
3-5 28.7 29.4 














Table 4.3. Age distribution of females between the pre- and post-vaccine periods 




14-19  years    N=1,660 N=887 
 
20–24 years N=551 N=513 
25–29 years N=523 N= 472 
 
30–39 years N=850 N= 1,034 
 
40–49 years N=795 N= 1,072 
 












                   Table 4.4. Non-vaccine-targeted HR HPV type prevalence among the entire sample of females  
  
HPV Type 
Prevalence % (95% CI) 
 
      2003-2006                     2007-2010 
      (N=4990)                         (N=4860) 
 
Unadjusted 
Prevalence Ratioa (95% CI) 
  
Adjustedb 




23.0 (21.5-24.5) 22.1 (20.7-23.5) 0.96 (0.88-1.1) 0.98 (0.88-1.08) 
Alpha-9 
speciesd 
7.7 (6.8-8.7) 6.4 (5.6-7.2) 0.83 (0.70-0.99)* 0.84 (0.69-1.03) 
Alpha-7 speciese 7.4 (6.41-8.37) 7.5 (6.56-8.46) 1.01 (0.85-1.22) 1.02 (0.83-1.24) 
                                     a Exponentiated prevalence ratios calculated using Zou’s “modified Poisson” regression model with a robust error variance64   
                                     b Adjusted for age, race/ethnicity, education, marital status, age at sexual debut, and number of total lifetime sexual partners   
                                     c HR non-vaccine HPV types combined (n=18): HPV 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 70, 73, and 82) 
                                     d Alpha-9 species combined: HPV 31, 33, 35, 52, and 58 (excluding HPV 16) 
                                     e
 Alpha-7 species combined: HPV 39, 45, 59, and 68 (excluding HPV 18) 











                  Table 4.5. Non-vaccine-targeted HR HPV prevalence in females stratified by age group  
Age HPV Type  
2003-2006 
(% & 95% CI) 
2007-2010 




  n= 1660 n= 887   
HR non-vaccine 
typeb* 
19.8 (17.3-22.3) 15.6 (12.6-18.5) 0.79 (0.63-0.99) 
Alpha-9 speciesc 6.9 (5.4-8.4) 5.2 (3.4-7.0) 0.76 (0.50-1.13) 
Alpha-7 speciesd 11.8 (8.4-15.2) 9.9 (5.6-14.2) 0.84 (0.50-1.41) 
20-24 y/o 
  n=551 n=558   
HR non-vaccine type 32.8 (27.9-37.7) 37.8 (32.7-42.8) 1.15 (0.94- 1.40) 
Alpha-9 species 13.6 (10.1-17.1) 12.3 (9.2-15.5) 0.91 (0.63-1.30) 
Alpha-7 species 12.6 (9.1-16.1) 15.22 (11.5-18.9) 1.21 (0.83-1.75) 
25-29 y/o 
  n=523 n=540   
HR non-vaccine type* 23.1 (18.5-27.7) 32.3 (27.3-37.4) 1.40 (1.09-1.80) 
Alpha-9 species 8.4 (5.3-11.5) 10.2 (7.1-13.2) 1.21 (0.75-1.94) 
 
Alpha-7 species 












                                          a Exponentiated prevalence ratios calculated using Zou’s “modified Poisson” regression model with a robust error variance64 
                                          b 
HR non-vaccine HPV  types combined ([n=18] HPV 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 70, 73, and 82) 
                                          c 
Alpha-9 species combined: HPV 31, 33, 35, 52, and 58 (excluding HPV 16) 
                                          d 
Alpha-7 species combined: HPV 39, 45, 59, and 68 (excluding HPV 18) 




Age HPV Type  
2003-2006 
(% & 95% CI) 
2007-2010 




  n=850 n=1,062   
HR non-vaccine type 23.5 (20.0-26.9) 21.3 (18.5-24.0) 0.91 (0.75-1.10) 
Alpha-9 species 7.3 (5.2-9.3) 5.1 (3.7-6.5) 0.70 (0.47-1.04) 
Alpha-7 species 7.7 (5.5-9.8) 6.9 (5.2-8.6) 0.90 (0.62-1.30) 
40-49 y/o 
  n=795 n=1,164   
HR non-vaccine type 22.4 (19.1-25.8) 20.5 (17.5-23.5) 0.91 (0.74-1.26) 
Alpha-9 species 7.0 (5.0-9.0) 4.9 (3.3-6.4) 0.70 (0.46-1.06) 
Alpha-7 species 5.6 (3.8-7.3) 6.6 (4.7-8.4) 1.18 (0.78-1.19) 
50-59 y/o 
  n=611 n=888   
HR non-vaccine type 19.7 (16.2-23.3) 15.8 (12.7-18.8) 0.80 (0.61-1.04) 
Alpha-9 species 6.0 (3.9-8.0) 5.3 (3.4-7.1) 0.88 (0.54-1.44) 
 
Alpha-7 species 






Table 4.6a. Weighted prevalence of HPV alpha 9 & 7 species among all females  
RSE: Relative Standard Error 
  




HPV Type Number  
positive 
Weighted %   (95% CI) Number 
positive 
Weighted %  (95% CI) 




N=438  7.7 (6.8-8.7) N=357  6.4 (5.6-7.2) 
31 N=133  2.2 (1.7-2.7) N=76  1.6 ( (1.1-2.0) 
33 N=56  1.5 (1.0-1.9) Suppressed: RSE of >30% or <10 observations 
35 N=64  1.3 (0.8-1.7) N=81  1.7 (1.2-2.1) 
52 N=177  3.5 (2.8-4.2) N=143  3.1 (2.5-3.7) 
58 N= 83 1.8 (0.9-1.7) N=84  1.4 (1.0-1.8) 




N=412 7.1 (6.2-8.0) N=368  7.1 (6.2-8.0) 
39 N=122  2.2 (1.7-2.7) N=113  2.7 (2.1-3.3) 
45 N=105  2.0 (1.5-2.5)  Suppressed: RSE of >30% or <10 observations   
59 N=151  2.9 (2.3-3.6) N=123  2.3 (1.8-2.8) 





Table 4.6b. Weighted prevalence of HPV alpha 9 & 7 species among females aged 14-19 years  
















HPV Type Number  
positive 
Weighted %   (95% CI) Number 
positive 
Weighted %  (95% CI) 




153  6.9 (5.4-8.4) 49  5.2 (3.4-7.0) 
31 56  2.7 (1.7-3.7) 9  1.2 ( (0.3-2.1) 
33 10  0.5 (0.1-0.8) Suppressed: RSE of >30% or <10 observations 
35 20  1.1 (0.5-1.7) 8  0.7 (1.2-1.1) 
52 65  3.6 (2.4-4.8) 26  3.8 (2.0-5.6) 
58 37 1.8 (1.0-2.7) 9  0.8 (0.2-1.4) 




146 6.5 (5.1-8.0) 56  5.2 (3.5-7.0) 
39 54  3.3 (2.1-4.5) 22  2.8 (1.2-4.3) 
45 29  1.4 (0.7-2.1) Suppressed: RSE of >30% or <10 observations 
59 62  3.1 (2.0-4.2) 28  3.0 (1.6-4.3) 





Table 4.6c. Weighted prevalence of HPV alpha 9 & 7 species among females aged 20-29 years 
  




HPV Type Number  
positive 
 
Weighted %   (95% CI) Number 
positive 
Weighted %  (95% CI) 




115 11.2 (8.8-13.6) 138  11.3 (9.3-13.4) 
31 26  2.4 (1.2-3.5) 44  3.5 (2.3-4.6) 
33 17   2.5 (1.2-3.8) 14  1.7 (0.7-2.7) 
35 20  2.2 (1.1-3.3) 38  3.8 (2.5-5.1) 
52 56  6.8 (4.7-8.9) 54  5.3 (3.7-6.9) 
58 18  1.9 (0.8-3.0) 20  1.42 (0.8-2.1) 




114  11.3 (8.9-13.7) 132  12.3 (10.0-14.6) 
39 39  4.5 (2.8-6.2) 60  6.8 (4.8-8.7) 
45 23  2.6 (1.3-3.9) 20  2.0 (1.1-3.0) 
59 41  5.3 (3.4-7.2) 36  3.4 (2.1-4.6) 





Table 4.6d. Weighted prevalence of HPV alpha 9 & 7 species among females aged 30-39 years 
  




HPV Type Number  
positive 
 
Weighted %   (95% CI) Number 
positive 
Weighted %  (95% CI) 




60  7.3 (5.2-9.3) 70  5.2 (3.8-6.5) 
31 20  2.2 (1.0-3.3) 16  1.5 (0.7-2.3) 
33 8  1.0 (0.3-1.8) 8  0.5 (0.2-0.9) 
35 7  1.0 (0.2-1.8) 16  1.4 (0.7-2.1) 
52 17  2.9 (1.3-4.4) 28  2.4 (1.4-3.5) 
58 13 1.7 (0.6-2.8) 12  0.8 (0.4-1.3) 




61  7.7 (5.5-9.8) 92 8.8 (6.7-10.5) 
39 11  1.4 (0.5-2.4) 20  2.7 (1.4-4.0) 
45 19  2.4 (1.1-3.6) 26  2.5 (1.4-3.5) 
59 20  3.2 (1.6-4.8) 26  2.6 (1.4-3.7) 





Table 4.6e. Weighted prevalence of HPV alpha 9 & 7 species among females aged 40-49 years 
  




HPV Type Number  
positive 
 
Weighted %   (95% CI) Number 
positive 
Weighted %  (95% CI) 




68 7.00 (5.0-9.0) 60  3.9 (2.7-5.0) 
31 18  2.1 (0.9-3.3) 14  0.8 (0.4-1.2) 
33 11 1.4 (0.4-2.4) 4  0.2 (0.0-0.5) 
35 10  1.0 (0.2-1.7) 10  0.5 (0.2-0.8) 
52 22  2.5 (1.3-3.8) 16  1.8 (0.7-2.8) 
58 10  0.9 (0.2-1.6) 22  1.4 (0.7-2.1) 




58 5.6 (3.8-7.2) 66  5.6 ((3.8-7.0) 
39         11        1.3 (0.3-2.3) 12  1.2 (0.4-2.0) 
45 21  1.7 (0.9-2.5) 18  1.6 (0.7-2.6) 
59 18  2.0 (0.9-3.2) 22  1.9 (0.0-2.9) 





Table 4.6f. Weighted prevalence of HPV alpha 9 & 7 species among females aged 50-59 years 
 
  




HPV Type Number  
positive 
 
Weighted %   (95% CI) Number 
positive 
Weighted %  (95% CI) 




42  6.0 (3.9-8.0) 54 5.0 (3.4-6.8) 
31 13  1.7 (0.6-2.8) 8  0.5 (0.1-0.9) 
33 10  1.7 (0.5-2.9) 12  1.2 (0.4-2.1) 
35 7  1.2 (0.2-2.3) 12  1.7 (0.5-2.9) 
52 17  2.1 (0.9-3.3) 22  2.7 (1.3-4.2) 
58 5  0.6 (0.0-1.1) 12  0.9 (0.4-1.4) 




33  4.3 (2.5-6.0) 52  4.4 (2.7-6.1) 
39 7  1.2 (0.1-2.2) 10  0.5 (0.2-0.9) 
45 13  1.7 (0.6-2.9) 6  0.9 (0.0-1.8) 
59 10  1.3 (0.4-2.3) 14  1.1 (0.3-2.0) 





Table 4.7. Weighted HPV prevalence according to vaccination status  
among females aged 14-29 years from the post-vaccine period (2007-2010) 
HPV Type 
 
Prevalence (%)  
  
  Unvaccinated            Vaccinateda            
     N=1,423                        N=412 
 
 
PR (95% CI)b 
HR non-vaccine typesc  23.9 30.3 1.27 (1.02-1.52)* 
Alpha-9 speciesd  7.6 10.8 1.43 (0.97-1.90) 
Alpha-7 speciese 8.5 13.4 1.58 (1.15-2.01)* 
 
 
Abbreviations: CI, confidence interval; PR, prevalence ratio; HR, high risk;  
a 
Vaccination defined as a self-reported history of receiving ≥1 vaccine dose  
b 




Non-vaccine-targeted HR HPV (18 genotype combined: HPV 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66,  
67, 68, 70, 73, & 82) 
d 
Alpha-9 species combined:  HPV 31, 33, 35, 52, and 58 (excluding HPV 16).  
e 









Table 4.8a. Weighted non-vaccine-targeted HR HPV prevalence in 2003-2006 among females who 
resided in one of the top-10 states with the highest HPV vaccine coverage compared to those who 
resided in one of the bottom-10 states with lowest HPV vaccine coverage 
HPV Type  Top-10 states in vaccine 
coverageb (combined)  
2003-2006 














According to 2010 NIS-Teen published data  
b 
Rhode Island; South Dakota; Massachusetts; Connecticut; Washington; Wisconsin; Nebraska; New Hampshire; Pennsylvania; Virginia 




Table 4.8b. Weighted non-vaccine-targeted HR HPV prevalence in 2007-2010 among females who 
resided in one of the top-10 states with the highest HPV vaccine coverage compared to those who 
resided in one of the bottom-10 states with lowest HPV vaccine coverage 
HPV Type  Top-10 states in vaccine 
coverage (combined)  
2007-2010 






































Table 4.9a. Multivariate GEE analysis of factors associated with non-vaccine-targeted HR HPV 












20-24 years 1.64 (1.36-1.97) <.0001 
25-29 years 1.35 (1.11-1.63) <0.01 
30-39 years 1.18 (0.99-1.41) 0.06 
40-49 years 1.08 (0.91-1.29) 0.37 
50-59 years Referent  
Race/ethnicity 
Non-Hispanic white  Referent  
Non-Hispanic black 1.15 (1.03-1.28) 0.01 
Mexican American 1.24 (1.09-1.42) 0.001 
Other 1.10 (0.94-1.30) 0.22 
Educationa 
Less than high school  1.20 (1.05-1.36) <0.01 
High school graduate 1.32 (1.17-1.49) <.0001 
More than high school Referent  
Marital status 
Married Referent  
Widowed/divorced/separated 1.70 (1.47-1.97) <.0001 
Never married 1.65 (1.43-1.90) <.0001 
Living with partner 1.58 (1.33-1.88) <.0001 
Age at sexual 
debut 
Never had sex Referent  
<16 Years 4.09 (1.49-11.26) <0.01 
>16 Years 4.03 (1.47-11.06) <0.01 
Total lifetime 
sex partners 
0 Referent  
1 0.40 (0.21-0.74) <0.01 
2 0.77 (0.42-1.43) 0.41 
3-5 1.22 (0.68-2.17) 0.51 
>6 1.52 (0.85-2.70) 0.16 
a
 Non-vaccine-targeted HR HPV (18 genotypes combined: HPV 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 












Table 4.9b. Multivariate GEE analysis of factors associated with non-vaccine-targeted HR HPV 













20-24 years 2.04 (1.39-2.99) <.001 
25-29 years 1.51 (1.02-2.23) 0.04 
30-39 years 1.12 (0.79-1.59) 0.53 
40-49 years 1.01 (0.71-1.42) 0.96 
50-59 years Referent  
Race/ethnicity 
Non-Hispanic white  Referent  
Non-Hispanic black 1.74 (1.40-2.15) <.0001 
Mexican American 1.45 (1.11-1.87) <.01 
Other 1.18 (0.84-1.67) 0.34 
Education 
Less than high school  0.96 (0.74-1.24) 0.77 
High school graduate 1.34 (1.06-1.71) 0.02 
More than high school Referent  
Marital status 
Married Referent  
Widowed/divorced/separated 2.18 (1.64-2.90) <.0001 
Never married 1.80 (1.33-2.43) <.001 
Living with partner 1.59 (1.06-2.30) 0.03 
Age at sexual 
debut 
Never had sex Referent  
<16 Years 2.07 (0.35-12.23) 0.42 
>16 Years 2.39 (0.40-14.06) 0.33 
Total lifetime 
sex partners 
0 Referent  
1 0.41 (0.12-1.43) 0.16 
2 0.78 (0.23-2.64) 0.69 
3-5 1.61 (0.62-5.09) 0.42 
>6 1.96 (0.62-6.20) 0.25 
a











Table 4.9c. Multivariate GEE analysis of factors associated with non-vaccine-targeted HR HPV 













20-24 years 3.13 (2.10-6.66) <.0001 
25-29 years 2.05 (1.36-3.10) <.001 
30-39 years 1.71 (1.18-2.49) <.01 
40-49 years 1.26 (0.86-1.85) 0.24 
50-59 years Referent  
Race/ethnicity 
Non-Hispanic white  Referent  
Non-Hispanic black 1.21 (0.96-1.52) 0.10 
Mexican American 1.37 (1.06-1.78) 0.02 
Other 1.14 (0.83-1.56) 0.42 
Education 
Less than high school  0.99 (0.76-1.29) 0.94 
High school graduate 1.30 (1.03-1.65) 0.03 
More than high school Referent  
Marital status 
Married Referent  
Widowed/divorced/separated 2.09 (1.55-2.83) <.0001 
Never married 1.61 (1.22-2.13) <.001 
Living with partner 1.40 (0.99-1.96) 0.05 
Age at sexual 
debut 
Never had sex Referent  
<16 Years 7.24 (1.28-41.01) 0.03 
>16 Years 6.97 (1.23-39.47) 0.03 
Total lifetime 
sex partners 
0 Referent  
1 0.39 (0.13-1.16) 0.09 
2 0.84 (0.29-2.43) 0.74 
3-5 1.15 (0.42-3.16) 0.78 
>6 1.50 (0.55-4.06) 0.43 
a
 Alpha-7 species combined: HPV 39, 45, 59, and 68 (excluding  HPV 18) 
  
 







Figure 4.1a. Top-10 states with the highest estimated HPV vaccination coverage                           
(all 3 doses) - NIS-Teen Survey, 2010                                          
 
 
Figure 4.1b. Bottom-10 States with the lowest estimated HPV vaccination coverage                     









Figure 4.2.  Individual non-vaccine-targeted HR HPV genotypic prevalence in females aged 14-19 years           
























*P<0.05; Missing bars in 2007-2010 denote a relative standard error of >30% or <10 outcomes 
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 Vaccination against invasive cervical cancer (ICC) began in 2006 with the commercial 
availability of the HPV quadrivalent vaccine, Gardasil.  With a median age of 49 years for ICC 
in the U.S.,
1
 significant clinical benefit of HPV vaccination—namely, a reduction in ICC 
incidence—will  not be evident for approximately 25 years.  In the interim, the CDC considers 
the study of early virologic effects of HPV vaccination to be a “critical aspect of monitoring its 
population impact.”
2
  Hence, the broad aim of this dissertation is to understand the early impact 
of HPV vaccination in females at the population level.   
 Three important public health questions were examined: 1) Is HPV vaccination doing 
what is expected: decreasing the prevalence of vaccine-type HPV 6, 11, 16 and 18; 2) Is there 
evidence of beneficial cross-protection (decreased prevalence) of any of the other non-vaccine-
targeted HR HPV genotypes etiologically linked to ICC?; and 3) With the expected decline of 
HPV 16 and 18, are there deleterious virological consequences, such as type-replacement 
(increased prevalence) with a rise of other HR HPV genotypes?  To answer these questions, I 
analyzed HPV DNA vaginal swab data on over 8,000 females participating in a population-
based, cross-sectional survey from 2003-2010.  In this final chapter, I summarize and synthesize 
the findings presented in Chapters 2, 3, and 4 with an overview of their public health impact and 
offer suggestions for future research.   
 
5.1 Summary of the Findings 
 Chapter 2 included a review and synthesis of the peer-reviewed literature published from 
2007 to 2013 that documented the early impact of HPV vaccination.  Seventeen ecological 





changes) and compared incidence or prevalence in a pre-HPV vaccination time period (pre-2007) 
with that of a post-vaccination time period (post-2007).  While the primary goal of the review 
was to determine incidence or prevalence change in females (the overwhelming majority of 
vaccine recipients), studies which included data on males were also reviewed.   
 All 17 analyzed studies with samples from the pre- and post-vaccine era (i.e., before and 
after 2007) demonstrated that HPV vaccination has had an immediate impact at the population 
level of reducing cervical abnormalities, genital warts (GW), and in markedly decreasing the 
prevalence of vaccine-type HPV infection.  Many of GW studies with male subjects documented 
significant decreased incidence or prevalence even though HPV vaccination coverage for this 
population was <5%.
3-7
 And most importantly, of the three studies categorizing males by sexual 
orientation, decreased incidence of GW was noted in men who have sex with women (MSW) but 
not in men who have sex with men (MSM).
3,5,7
      
 Chapter 3 investigated early virologic impact of HPV vaccination at the population level 
and the expected outcome of decreased vaccine-type HPV genotypic prevalence in over 8,000 
females aged 14-59 years enrolled in the NHANES HPV Vaginal Swab Surveys from 2003-
2010.  I found that prevalence of HPV 6 was less in all females irrespective of vaccine status in 
the post-vaccine period.  There was also a profound decrease of combined low-risk (LR) and HR 
vaccine-type HPV prevalence in females aged 14-19 years from the post-vaccine period 
compared to the pre-vaccine period.  When comparing self-reported vaccinated to unvaccinated 
females in the post-vaccine period, the only statistically significant prevalence difference 
observed was a reduction in combined LR vaccine-type HPV.  Lastly, no difference in vaccine-





top-10 states with the highest vaccine coverage compared to those in the bottom-10 states with 
the least vaccine coverage.  
 Chapter 4 tested for evidence of non-vaccine-targeted HR HPV genotypic cross-
protection (decreased prevalence) and type-replacement (increased prevalence) in females from 
the NHANES HPV Vaginal Swab Surveys.  There was evidence of cross-protection with an 
observed prevalence decrease of non-vaccine-targeted HR HPV when comparing pre- and post-
vaccine period adolescent females irrespective of vaccination status.  In contrast, there was 
significantly higher prevalence of combined non-vaccine-targeted HR HPV and HR HPV from 
the alpha-7 species in vaccinated females compared to those unvaccinated.  The increase of 
combined non-vaccine-targeted HR HPV prevalence in our sample of vaccinated females is 
suggestive of genotypic type-replacement and confirms similar results from a smaller, recently 
published U.S. study.
8
  The prevalence increase of individual genotypes in vaccinated females 
did not reach statistical significance because of decreased power, limited observations and small 
cells.  
 
5.2 Implications of the Findings  
 The results from the literature review confirm many of the findings of the pivotal phase 




 and they mimic the positive virologic and clinical 
outcomes of HPV vaccination that have been widely documented in numerous mathematical 
modeling studies.
11-16
  In this first decade of HPV vaccination, it is encouraging to observe 





 The most salient finding, that there has been a substantial decrease in incidence of GW in 
Australian young MSW but not MSM—where the rate of female vaccination with the original 
quadrivalent Gardasil was 70-80%
17
 and male vaccination was <5%—demonstrates that young 
vaccinated females provide some form of herd immunity to young MSW.
18-21
  
 Unfortunately, this evidence of herd immunity in young MSW, along with a few 
editorials
22,23
  and some modeling studies indicating that vaccinating boys is not cost effective,
24-
26
  was used as the justification  by the UK’s Joint Committee on Vaccination and Immunisation 
(JCVI) to initially recommend against vaccinating males to the UK Ministry of Health.
27
  Only 
after strong opposition from medical associations and advocacy groups
28
 did the JCVI partially 
compromise to recommend only MSM be vaccinated because of their increased risk of anal 
cancer.
29-31
  The JCVI’s most recent recommendations read:  
Given the evidence available and the modelling work undertaken JCVI advises that a 
targeted HPV vaccination programme for MSM aged up to 45 who attend GUM and HIV 
clinics should be undertaken, subject to procurement of the vaccine and delivery of the 
programme at a cost-effective price.
32 
 
 This compromise is scientifically unsound and illogical for two important reasons: 1) 
regardless of the possible herd immunity data on decreased incidence of GW, no data exist on 
herd immunity against head and neck cancers in MSW which we clearly know are etiologically 
linked to HPV 16;
33-37
  and 2) if the vaccination is to be effective, it must be administered to 
adolescent males before they become sexually active.  Can we expect adolescent males to know 
and be certain of their life-long sexual preference?        
  The documentation of marked prevalence reduction of HPV 16 in NHANES post-





prevalent carcinogenic genotype in the general population and consistently identified in >50% of 
cervical cancers worldwide.
38,39
  These data of the vaccine’s potent virologic activity at the 
population level in preventing HPV 16 will offer healthcare professionals further proof of the 
vaccine’s effectiveness and can be used to advocate for increased HPV vaccination coverage of 
both young females and males.  Likewise, physicians must do a better job in educating parents 
and dissuading them of the belief that HPV vaccination is “not necessary or needed.”
40
  
Undoubtedly, greater vaccine uptake in females with the understanding that the vaccine is doing 
what it’s meant to—preventing a cancer-causing virus—will undoubtedly help normalize and 
increase HPV vaccine uptake in males to prevent anal, penile, and head and neck cancers.    
 The marked increased prevalence of combined non-vaccine-targeted HR HPV in 
vaccinated compared to non-vaccine females who predominantly received the original 
quadrivalent Gardasil is suggestive of type-replacement and could have significant public health 
implications.  While the recently approved Gardasil-9 with its nonavalent structure will now 
protect individuals against most of the highly carcinogenic genotypes from the alpha 7 and 9 
species, over 200 million doses of the original Gardasil have been administered—mostly to 
females—since 2006.
18
  This possibility of type-replacement with carcinogenetic HR HPV 
genotypes now adds additional emphasis to the American College of Obstetricians and 
Gynecologists (ACOG) cervical cancer screening guidelines which state: “Women who have 
received the HPV vaccine should be screened according to the same guidelines as women who 
have not been vaccinated.”
41
  
 Our observation of markedly decreased prevalence of both LR and HR vaccine-type HPV 
in vaccinated compared to unvaccinated females (Chapter 3, Table 6) clearly demonstrates 





decrease in vaccine-type prevalence in our samples of post-vaccine period adolescent females—
irrespective of vaccination—is due, in part, to herd immunity.  Most sexually transmitted 
infection mathematical models document that a sizable threshold of vaccine coverage is 
necessary for herd immunity.
20,42,43
  Because HPV vaccine efficacy is documented to be >90%,  




 Thus, it is plausible for Australian researchers to cite herd immunity as the reason for 
marked decreased vaccine-type HPV prevalence in the post-vaccine period sample of females 
with mixed vaccine status from their ecological study.
46
  The rate of HPV vaccination (for all 3 
doses) in Australian female adolescents during the study period was ~70.
17
  However, claiming 
herd immunity in our ecological analyses of NHANES data seems inappropriate when the 




 Lastly, a thorny methodological issue which needs addressing is the number of ecological 
studies (including one from the CDC) that classify females as vaccine exposed if they’ve had 
only one of the three USPHS recommended doses.
8,46,48,49
   For consistency and the ability to 
compare my data with other ecological studies, I felt obliged to follow suit with equating >1 dose 
as exposed.   
 It turns out that immunogenicity data from randomized trials in females receiving less 
than three doses,
50-53
  as well as a recently published cohort study documenting protection 
against CIN
54
 in those who had one or two doses, demonstrates considerable vaccine benefit.  





of Experts (SAGE) on immunization issued a recommendation and European Medicines Agency 
(EMA) granted marketing authorization for a 2-dose schedule with an interval of at least 6 
months between doses for girls aged <15 years.
55,56
  The WHO’s SAGE contends:  
SAGE recognized that a reduction from 3 to 2 vaccine doses would bring major cost 
savings as well as obvious programmatic advantages, and that an increased flexibility in 




While I agree that there is a tremendous need to improve vaccine coverage and cost 
savings (especially in lesser developed countries), I think that these recommendations were 
premature.  First, the long-term duration of immunogenicity of two doses compared to three has 
not been measured beyond three years.  Secondly, these organizations should have waited for the 
results of the large, multinational, phase 3 randomized controlled trials of Gardasil-9 and 
Cervarix which are both comparing the immunogenicity of two versus three vaccine doses in 
young females.
57,58
   
 
 
5.3  Future Directions in Research & Public Policy Recommendations 
 Ecological studies assessing temporal trends in vaccine-type and non-vaccine-type HPV 
prevalence in males should be commenced.  If these studies can obtain physician-verified 
vaccine history of participants as well as male sexual behavior (e.g., heterosexual or 
homosexual), it may be possible to determine if decreased HPV prevalence is due, in part, to the 
effect of herd immunity.   
 Because the three-dose vaccination completion rate was so low (7.4%) in our adolescent 
females who reported a history of vaccination, it was not possible to compare genotypic 





countries with established vaccination programs completely change to a two-dose HPV vaccine 
regimen (based on guidelines using immunogenicity data), it will be prudent to compare HR 
HPV DNA genotypic prevalence in large samples of women who received two versus three 
doses.     
 Further study is warranted to confirm our observation of increased prevalence of non-
vaccine-targeted HR HPV in vaccinated females who received the original Gardasil.  HPV DNA 
cross-sectional studies could be undertaken in Australia and European countries with vaccine 
registries and well organized cervical cancer screening programs.  If a pre-vaccine era cohort 
does not exist, it is possible that saved HPV DNA vaginal swab samples before 2007 could serve 
as historical controls.  It will also be necessary to ascertain if there is increased prevalence of 
non-vaccine-targeted HR HPV in colposcopy tissue samples in women with high-grade CIN.  
 With such strong mounting evidence of early vaccine virologic activity and a stellar 
safety profile, it is time for public health officials to strongly consider mandatory HPV 
vaccination for all school-aged females across the U.S.  To date, only Virginia, Rhode Island and 
Washington, DC require HPV vaccination of adolescent females for school entry.
59
  By 
employing the model of Hepatitis B Virus (HBV) vaccination programs, this will be the surest 




 Finally, with 84% of the 270,000 deaths attributed to cervical cancer occurring in 
developing counties,
61
  it is welcome news that Merck and GlaxoSmithKline awarded UNICEF 
contracts to procure Gardasil and Cervarix to females in developing countries at significantly 
reduced prices.
62





girls in 28 countries by 2020.
63
  It is imperative that ministries of health make HPV vaccination 
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Aim: Examine whether the results presented in Chapters 3 and 4 would change depending on 
log-binomial or modified Poisson regression models employed for adjusting prevalence ratios 
(PRs) for potential confounders.  
Method:  Data were drawn from more than 8,000 females aged 14-59 years enrolled between 
2003 and 2010 in the NHANES HPV Vaginal Swab Surveys, a population-based, cross-sectional 
survey collecting HPV DNA specimens.  HPV genotypic prevalence was compared between 
females from the first two 2-year surveys (2003-2004 and 2005-2006; the “pre-vaccine period”) 
and females from the latter two 2-year surveys (2007-2008 and 2009-2010; the “post-vaccine 
period”).   
Results: Adjusted PRs, 95% confidence intervals (CIs), and p-values were markedly different in 
both models.  In comparison to the modified Poisson models, the log-binomial models had issue 
with convergence, produced unreliable PRs, exceedingly narrow CIs and found all estimates to 
be statistically significant.  (See Tables 1a, 1b, 2a, and 2b).  For example, with vaccine-type LR 
HPV prevalence at 2.6% (95% CI: 2.0-3.2) in the pre-vaccine period and 1.6% (95% CI: 1.2-2.0) 
in the post-vaccine period, the log-binomial model’s statistically significant aPR was 0.9939 
(95% CI: 0.9938-0.9940) compared to the modified Poisson model’s non-statistically significant 
aPR of 0.81 (95% CI: 0.55-1.19). 
Conclusion: Results radically changed between models. The modified Poisson regression model 
produced more precise and conservative adjusted PRs with less overly narrow CIs than the log-










                Table 1a. HPV prevalence among females aged 18-59 years using a “log binomial” regression modela  
  
HPV Type 
Prevalence % (95% CI) 
 
2003-2006  (N=3906)             2007-2010 (N=4488) 
Adjustedh 
Prevalence Ratio (95% CI) 
Any HPVb  38.5 (36.6-40.4) 37.5 (35.8-39.2) 0.9679 (0.9678-0.9681)* 
All vaccine typec 7.8 (6.8-8.9) 6.9 (6.1-7.8) 0.9981 (0.9979-0.9982)* 
HR vaccine typed 5.6 (4.7-6.5) 5.6 (4.8-6.4) 1.0031 (1.0029-1.0032)* 
LR vaccine typee 2.6 (2.0-3.2) 1.6 (1.2-2.0) 0.9939 (0.9938-0.9940)* 
HR non-vaccine typef 23.9 (22.2-25.5) 23.1 (21.7-24.6) 0.9812 (0.9811-0.9814)* 
Alpha-9 speciesg 8.0 (6.9-9.0) 6.4 (5.6-7.2) 0.9832 (0.9831-0.9834)* 
a
 Log-binomial regression model as per Spiegelman & Hertzmark, Am J Epidemiol 2005;162:199–200. 
b 
All genotypes combined (n=37)HPV 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, XR(52), 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72,                                                           
73, 81, 82, 83, 84, 89, and IS39 
c
 All vaccine types: HPV 6, 11, 16, and 18 (combined) 
d  
HR vaccine type: HPV 16 and/or 18 
e 
LR vaccine type: HPV 6 and/or 11 
f 
HR non-vaccine-type combined (n=18): HPV 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 70, 73, and 82) 
g
 Alpha-9 species combine: HPV 31, 33, 35, 52, and 58 (excluding HPV 16) 
h 
















                 Table 1b. HPV prevalence among females aged 18-59 years using a “modified Poisson” regression modela 
  
HPV Type 
Prevalence % (95% CI) 
2003-2006 (N=3906)               2007-2010 (N=4488) 
Adjustedh 
Prevalence Ratio (95% CI) 
Any HPVb  38.5 (36.6-40.4) 37.5 (35.8-39.2) 0.96  (0.89-1.03) 
All vaccine typec 7.8 (6.8-8.9) 6.9 (6.1-7.8) 0.99 (0.81-1.2) 
HR vaccine typed 5.6 (4.7-6.5) 5.6 (4.8-6.4) 
Convergence problem & 
failure to provide an aPR 
estimate 
LR vaccine typee 2.6 (2.0-3.2) 1.6 (1.2-2.0) 0.81 (0.55-1.19) 
HR non-vaccine typef 23.9 (22.2-25.5) 23.1 (21.7-24.6) 0.98 (0.88-1.08) 
Alpha-9 speciesg 8.0 (6.9-9.0) 6.4 (5.6-7.2) 0.84 (0.69-1.03) 
a
 “Modified Poisson” regression model as per Zou, Am J Epidemiol 2004;159:702–6.. 
b 
All genotypes combined (n=37)HPV 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, XR(52), 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72,                                                                   
73, 81, 82, 83, 84, 89, and IS39 
c
 All vaccine types: HPV 6, 11, 16, and 18 (combined) 
d  
HR vaccine type: HPV 16 and/or 18 
e 
LR vaccine type: HPV 6 and/or 11 
f 
HR non-vaccine-type combined (n=18): HPV 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 70, 73, and 82) 
g
 Alpha-9 species combine: HPV 31, 33, 35, 52, and 58 (excluding HPV 16) 
h 
Adjusted for age, race/ethnicity, education, marital status, country of birth, age at sexual debut, and total lifetime sex partners;  
* <0.05 
 
      









                              Table 2a. HPV weighted prevalence in females stratified by age group using a “log binomial” modela 
Age HPV Type  2003-2006                          
(% & 95% CI) 
2007-2010                             
(% & 95% CI) 
Prevalence Ratio                   
(95% CI) 
18-19 y/o  n=576 n=276  
Any HPVb  40.8 (35.3-46.3) 37.6 (30.3-44.9) 0.9683 (0.9677-0.9690)* 
HR vaccine-typec  12.1 (8.3-15.8) 4.9 (2.3-7.5) 0.9308 (0.9304-0.9311)* 
HR non-vaccine typed 31.6 (26.5-36.8) 27.6 (20.9-34.3) 0.9607 (0.9600-0.9613)*  
Alpha-9 speciese 10.9 (7.7-14.2) 7.9 (3.9-11.8) 0.9699 (0.9695 0.9703)* 
20-24 y/o  n=551 n=558  
Any HPV 44.8 (39.7-50.0) 54.2 (49.4-59.1) 1.0986 (1.0981-1.0991)* 
HR vaccine-type  12.7 (9.0-16.3) 12.9 (9.5-16.3) 1.0024 (1.0021-1.0027)* 
HR non-vaccine type 32.8 (27.9-37.7) 40.6 (35.7-45.4) 1.0803 (1.0799 1.0808)* 
Alpha-9 species 13.6 (10.1-17.1) 13.1 (9.9-16.2) 0.9946 (0.9943-0.9949)* 
25-29 y/o  n=523 n=540  
Any HPV 39.7 (34.6-45.4) 45.4 (40.5-50.3) 1.0562 (1.0558-1.0567)* 
HR vaccine-type 6.9 (4.1-9.8) 9.6 (6.7-12.6) 1.0276 (1.0273-1.0278)* 
HR non-vaccine type 23.1 (18.5-27.7) 30.3 (25.8-34.8) 1.0744 (1.0740-1.0748)* 
Alpha-9 species 8.4 (5.3-11.5) 9.8 (7.1-12.4) 1.0136 (1.0133-1.0138)* 
30-39 y/o  n=850 n=1,062  
Any HPV 38.8 (34.8-42.8) 34.0 (30.8-37.2) 0.9529 (0.9526-0.9531)* 
HR vaccine-type 5.9 (3.9-7.8) 4.8 (3.4-6.2) 0.9893 (0.9892-0.9895)* 
HR non-vaccine type 23.5 (20.0-26.9) 22.5 (19.7-25.3) 0.9906 (0.9903-0.9908)* 
Alpha-9 species 7.3 (5.2-9.3) 5.2 (3.8-6.5) 0.9794 (0.9793-0.9796)* 
40-49 y/o  n=795 n=1,164  
Any HPV 37.6 (33.6-41.6) 34.3 (31.0-37.6) 0.9678 (0.9675-0.9680)* 
HR vaccine-type 3.0 (1.5-4.5) 3.7 (2.5-5.0) 1.0073 (1.0072-1.0074)* 
HR non-vaccine type 22.4 (19.1-25.8) 17.0 (14.4-19.7) 0.9475 (0.9473-0.9478)* 
Alpha-9 species 7.0 (5.0-9.0) 3.9 (2.7-5.0) 0.9694 (0.9693-0.9695)* 
50-59 y/o  n=611 n=888  
Any HPV 34.7 (30.5-39.0) 31.0 (27.1-34.8) 0.9636 (0.9633-0.9639)* 
HR vaccine-type 2.6 (1.2-4.0) 3.1 (1.7-4.4) 1.0048 (1.0047-1.0049)* 
HR non-vaccine type 19.7 (16.2-23.3) 16.6 (13.5-19.7) 0.9690 (0.9687-0.9692)* 
Alpha-9 species 6.0 (3.9-8.0 5.1 (3.4-6.8) 0.9910 (0.9909 0.9912)* 
a 
Log-binomial regression model as per Spiegelman & Hertzmark, Am J Epidemiol 2005;162:199–200. 
b
All 37 genotypes: (HPV 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, XR(52), 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72,                                                                             
73, 81, 82, 83, 84, 89, and IS39). 
c
HR vaccine type: HPV 16 and/or 18 
d
HR HPV non-vaccine types combined ([n=18] HPV 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 70, 73, and 82) 
e











                        Table 2b. HPV weighted prevalence in females stratified by age group using a modified Poisson  regression modela  
Age HPV Type  
2003-2006 
(% & 95% CI) 
2007-2010 




  n=576 n=276   
Any HPVb 40.8 (35.3-46.3) 37.6 (30.3-44.9) 0.92 (0.73-1.17) 
HR vaccine-typec 12.1 (8.3-15.8) 4.9 (2.3-7.5)   0.41 (0.22-0.75)* 
HR non-vaccine typed 31.6 (26.5-36.8) 27.6 (20.9-34.3) 0.87 (0.65-1.17) 
Alpha-9 speciese 10.9 (7.7-14.2) 7.9 (3.9-11.8) 0.72 (0.40-1.29) 
20-24 y/o 
  n=551 n=558   
Any HPV 44.8 (39.7-50.0) 54.2 (49.4-59.1)   1.21 (1.02-1.43)* 
HR vaccine-type  12.7 (9.0-16.3) 12.9 (9.5-16.3) 1.02 (0.64-1.62) 
HR non-vaccine type 32.8 (27.9-37.7) 40.6 (35.7-45.4) 1.24 (0.99-1.55) 
Alpha-9 species 13.6 (10.1-17.1) 13.1 (9.9-16.2) 0.96 (0.63-1.26) 
25-29 y/o 
  n=523 n=540   
Any HPV 39.7 (34.6-45.4) 45.4 (40.5-50.3) 1.14 (0.93-1.39) 
HR vaccine-type 6.9 (4.1-9.8) 9.6 (6.7-12.6) 1.39 (0.77-2.52) 
HR non-vaccine type 23.1 (18.5-27.7) 30.3 (25.8-34.8) 1.31 (0.98-1.75) 
Alpha-9 species 8.4 (5.3-11.5) 9.8 (7.1-12.4) 1.16 (0.68-1.98) 
30-39 y/o 
  n=850 n=1,062   
Any HPV 38.8 (34.8-42.8) 34.0 (30.8-37.2) 0.88 (0.74-1.03) 
HR vaccine-type 5.9 (3.9-7.8) 4.8 (3.4-6.2) 0.82 (0.48-1.39) 
HR non-vaccine type 23.5 (20.0-26.9) 22.5 (19.7-25.3) 0.96 (0.76-1.20) 
Alpha-9 species 7.3 (5.2-9.3) 5.2 (3.8-6.5) 0.71 (0.45-1.13) 
40-49 y/o 
  n=795 n=1,164   
Any HPV 37.6 (33.6-41.6) 34.3 (31.0-37.6) 0.91 (0.77-1.09) 
HR vaccine-type 3.0 (1.5-4.5) 3.7 (2.5-5.0) 1.24 (0.63-2.47) 
HR non-vaccine type 22.4 (19.1-25.8) 17.0 (14.4-19.7) 0.76 (0.58-0.99)* 
Alpha-9 species 7.0 (5.0-9.0) 3.9 (2.7-5.0) 0.55 (0.33-0.93)* 
50-59 y/o 
  n=611 n=888   
Any HPV 34.7 (30.5-39.0) 31.0 (27.1-34.8) 0.89 (0.72-1.11) 
HR vaccine-type 2.6 (1.2-4.0) 3.1 (1.7-4.4) 1.18 (0.52-2.68) 
HR non-vaccine type 19.7 (16.2-23.3) 16.6 (13.5-19.7) 0.84 (0.61-1.15) 
Alpha-9 species 6.0 (3.9-8.0 5.1 (3.4-6.8) 0.85 (0.47-1.53) 
a  
“Modified Poisson” regression model as per Zou, Am J Epidemiol 2004;159:702–6. 
b 
All 37 genotypes: (HPV 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, XR(52), 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72,                                                                                    
73, 81, 82, 83, 84, 89, and IS39). 
c 
HR vaccine type: HPV 16 and/or 18 
d 
HR HPV non-vaccine types combined ([n=18] HPV 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 70, 73, and 82) 
e 
All Alpha-9 species combined: HPV 31, 33, 35, 52, and 58 (excluding HPV 16);  *<0.05 
